WO2000012762A1 - Nouvelle proteine liee a la proteine inhibitrice des melanomes et utilisation de cette nouvelle proteine - Google Patents

Nouvelle proteine liee a la proteine inhibitrice des melanomes et utilisation de cette nouvelle proteine Download PDF

Info

Publication number
WO2000012762A1
WO2000012762A1 PCT/US1999/020032 US9920032W WO0012762A1 WO 2000012762 A1 WO2000012762 A1 WO 2000012762A1 US 9920032 W US9920032 W US 9920032W WO 0012762 A1 WO0012762 A1 WO 0012762A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
tango
nucleic acid
polypeptide
amino acid
Prior art date
Application number
PCT/US1999/020032
Other languages
English (en)
Inventor
Yang Pan
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Priority to AU57020/99A priority Critical patent/AU5702099A/en
Publication of WO2000012762A1 publication Critical patent/WO2000012762A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Definitions

  • MIA Melanoma-Inhibiting Protein
  • MIA expression is enhanced in developing cartilage and in chondrosarcoma (Bosserhoff et al. (1997) Dev. Dyn. 208:516). Based on this data, a biological role for MIA in embryonic cell growth and morphogenesis has been suggested, and a therapeutic application of MIA in the development of an antitumor therapeutic has been proposed. Additionally, MIA expression correlates with progressive malignancy of melanocytic lesions (Bosserhoff et al. (1997) J. Biol. Chem. 271 :490), and MIA protein levels are enhanced in serum of patients with malignant melanoma (Bosserhoff et al. (1997) Cancer Res. 57:3149), supporting another proposed use of MIA as a marker of cancer progression.
  • CD-RAP for cartilage derived RA-sensitive protein
  • RA retinoic acid
  • Dietz & Sandell (1996) J. Biol. Chem. 271 :3311).
  • Retinoic acid is involved in the growth and differentiation of a variety of tissues, including the central nervous system, skin, and skeleton.
  • RA increases the expression of the transcription factor AP-2, which has been shown to regulate CD-RAP transcription.
  • the regulation of CD- RAP by AP-2 and the observed effects of RA on CD-RAP expression suggest that CD-RAP may participate in growth or developmental processes regulated by RA, or in other RA-regulated processes.
  • MIA/CD-RAP Homologues of MIA/CD-RAP appear to be present in a variety of tissues, including rat mammary carcinoma (GenBankTM Accession Number U67884), mouse mammary gland (GenBankTM Accession Numbers AA982842 and AA960553), mouse hypothalamus (GenBankTM Accession Number AA967578), human fetal heart (GenBankTM Accession Numbers AA062943, AA035545, W94322, W74647, W75984).
  • the discovery of MIA/CD-RAP homologues in cancer cells and developing tissues suggests a common developmental role for the members of this family.
  • the present invention is based, at least in part, on the discovery of a gene encoding TANGO 130, a secreted protein which shares homology to
  • the mouse TANGO 130 cDNA described below (SEQ ID NO:l) has a 2145 nucleotide open reading frame (nucleotides 24 - 2168 of SEQ ID NO:l; SEQ ID NO:2) which encodes a 714 amino acid protein (SEQ ID NO:3).
  • This protein includes a predicted signal sequence of about 24 amino acids (from amino acid 1 to about amino acid 24 of SEQ ID NO:3; SEQ ID NO:5) and a predicted mature protein of about 690 amino acids (from about amino acid 25 to amino acid 714 of SEQ ID NO:3; SEQ ID NO:4).
  • the human TANGO 130 described below has a 1230 nucleotide open reading frame (nucleotides 34 to 1263 of SEQ ID NO:7; SEQ ID NO:8) which encodes a 410 amino acid protein (SEQ ID NO:9).
  • the protein includes a predicted signal sequence of about amino acids (from amino acid 1 to about amino acid 23 of SEQ ID NO:10; SEQ ID NO:l 1) and a predicted mature protein of about 387 amino acids (from about amino acid 24 to amino acid 387 of SEQ ID NO:9; SEQ ID NO: 10).
  • Mouse and human TANGO 130 proteins possess a MIA homology domain (described below) at their amino terminus (amino acids 1 - 125; SEQ ID NO: 6 shows mouse, SEQ ID NO: 12 shows human).
  • the MIA homology domain contains four cysteines, conserved in both human and mouse TANGO 130 and is believed to be important to the molecules' structure and function.
  • the amino acid sequence of the mouse TANGO 130 MIA homology domain is 36% identical to human MIA, while the human TANGO 130 MIA homology domain is 38% identical to human MIA.
  • MIA and its bovine orthologue, CD-RAP participate in activities involving cellular proliferation. These molecules inhibit the growth of melanocytes and chondrosarcoma tumor cells, and therefore have therapeutic utility in the treatment of malignant melanoma and chondrosarcoma. Additionally, they are abundantly expressed in malignant melanoma and are useful as serum markers of metastatic melanoma.
  • molecules related to MIA and CD-RAP e.g., TANGO 130 molecules, can be used to treat patients with such metastatic tumors.
  • TANGO 130 molecules of the invention which are overexpressed in abnormal cells can be used as serum markers in the diagnosis and monitoring of associated disease states.
  • MIA and CD-RAP are active in the process of cellular differentiation, being found in developing cartilaginous tissues from the onset of chondrogenesis and throughout development.
  • CD-RAP expression is sensitive to retinoic acid, which functions in the growth and differentiation of the central nervous system, skin and skeleton.
  • the transcription factor AP-2 which increases in response to retinoic acid, binds to the CD-RAP promotor and inhibits CD-RAP transcription.
  • modulation of CD-RAP can result in the modulation of retinoic acid or AP-2 function.
  • Molecules related to CD-RAP e.g., TANGO 130 molecules, also function in cell differentiation pathways, e.g., pathways involving retinoic acid and/or AP-2.
  • the finding of TANGO 130 expression in mouse embryo throughout development supports a role for TANGO 130 in cellular differentiation.
  • TANGO 130 molecules of the invention which modulate the function of factors involved in cellular differentiation are therefore useful in modulating responses involved in related disorders, e.g., developmental disorders.
  • MIA also has therapeutic utility as an immunosuppressive agent.
  • Interleukin 2-dependent and phytohaemagglutmin- induced proliferation of peripheral blood lymphocytes are suppressed by MIA, as is the cytotoxicity of T lymphocytes (Canadian Patent Application Number 2,167,693).
  • TANGO 130 molecules of the invention which modulate the proliferation of immune cells have utility as modulators of immune function.
  • this invention provides isolated nucleic acid molecules encoding TANGO 130 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of TANGO 130-encoding nucleic acids.
  • the invention features a nucleic acid molecule which is at least 45% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Accession Number 98823 (the "cDNA of ATCC 98823”), the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Accession Number (the "cDNA of ATCC "), or a complement thereof.
  • the invention features a nucleic acid molecule which includes a fragment of at least 500 (550, 600, 650, 700, 800, 900, 1000, or 1290) nucleotides of the nucleotide sequence shown in SEQ ID NO:7, the nucleotide sequence of the cDNA of ATCC 98823 or a complement thereof; or includes a fragment of at least 500 (550, 600, 650, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, or 3000) nucleotides of the nucleotide sequence shown in SEQ ID NO:l, the nucleotide sequence of the cDNA of ATCC or a complement thereof.
  • the invention also features a nucleic acid molecule which includes a nucleotide sequence encoding a protein having an amino acid sequence that is at least 45% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, the amino acid sequence encoded by the cDNA of ATCC 98823 or the amino acid sequence encoded by the cDNA of ATCC .
  • a TANGO 130 nucleic acid molecule has the nucleotide sequence shown SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO: 7, SEQ ID NO:8, the nucleotide sequence of the cDNA of ATCC 98823, or the nucleotide sequence of the cDNA of ATCC .
  • nucleic acid molecule which encodes a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:9.
  • the fragment includes at least 135 (200, 300, 400, 500, 600, 714) contiguous amino acids of SEQ ID NO:3 or the polypeptide encoded by the cDNA of ATCC , or includes at least 15 (25, 30, 50, 100, 150, 200,
  • the invention includes a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, an amino acid sequence encoded by the cDNA of ATCC 98823, or an amino acid sequence encoded by the cDNA of ATCC wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:l, SEQ ID NO:7, the cDNA of ATCC 98823, or the cDNA of ATCC , or a complement thereof under stringent conditions.
  • an isolated TANGO 130 protein having an amino acid sequence that is at least about 45%, preferably 50%, 60%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:4, the amino acid sequence of SEQ ID NO:3, the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO:9; and an isolated TANGO 130 protein having an amino acid sequence that is at least about 45%, 50%, 60%, 70%, 85%, 95%, or 98%) identical to the MIA homology domain of SEQ ID NO:6 or SEQ ID NO: 12 (e.g., about amino acid residues 1 to 125 of SEQ ID NO:3 or SEQ ID NO:9).
  • an isolated TANGO 130 protein which is encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 45%, preferably 55%, 65%, 75%, 85%, or 95% identical to SEQ ID NO:2, SEQ ID NO:8, the cDNA of ATCC 98823, or the cDNA of ATCC ; an isolated TANGO 130 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 45%, preferably 55%, 65%), 75%, 85%), or 95% identical to the MIA homology domain encoding portion of SEQ ID NO:l or SEQ ID NO:7 (e.g., about nucleotides 24 to 398 of SEQ ID NO:l or nucleotides 34 to 408 of SEQ ID NO:7); and an isolated TANGO 130 protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to
  • SEQ ID NO:8 the cDNA of ATCC 98823, the cDNA of ATCC , or a complement thereof.
  • polypeptide which is a naturally occurring allelic variant of a polypeptide that includes the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 12, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number 98823, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number , wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, or the cDNA of ATCC , or a complement thereof under stringent conditions.
  • TANGO 130 nucleic acid molecules which specifically detect TANGO 130 nucleic acid molecules relative to nucleic acid molecules encoding related molecules, e.g., MIA or CD-RAP.
  • a TANGO 130 nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:
  • the TANGO 130 nucleic acid molecule is at least 500 (550, 600, 650, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, or 3000) nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:7, the cDNA of ATCC 98823, the cDNA of ATCC , or a complement thereof.
  • an isolated TANGO 130 nucleic acid molecule comprises nucleotides 24 to 398 of SEQ ID NO:l (SEQ ID NO:6) or nucleotides 34 to 408 of SEQ ID NO:7 (SEQ ID NO: 12), encoding the MIA homology domain of TANGO 130, or a complement thereof.
  • the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a TANGO 130 nucleic acid.
  • Another aspect of the invention provides a vector, e.g., a recombinant expression vector, comprising a TANGO 130 nucleic acid molecule of the invention.
  • the invention provides a host cell containing such a vector.
  • the invention also provides a method for producing TANGO 130 protein by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector such that a TANGO 130 protein is produced.
  • Another aspect of this invention features isolated or recombinant TANGO 130 proteins and polypeptides.
  • Preferred TANGO 130 proteins and polypeptides possess at least one biological activity possessed by naturally occurring human TANGO 130, e.g., (1) the ability to form protei protein interactions with proteins in the TANGO 130 signaling pathway; (2) the ability to bind TANGO 130 receptor; or (3) the ability to bind to an intracellular target.
  • Other activities include: (1) the ability to modulate, e.g., inhibit, cell proliferation (e.g., proliferation of cells of the kidney, liver, heart, testis, immune system, skin, cartilage, skeleton, skeletal muscle and central nervous system), e.g., abnormal cell proliferation, e.g., malignant cell proliferation, e.g., malignant proliferation of epithelial cells (e.g., carcinomas, e.g., melanomas), malignant proliferation of mesenchymal cells (e.g., sarcomas, e.g., chondrosarcomas, glioblastomas); (2) the ability to modulate cell-cell interactions, e.g., cell adhesion, or cell-substrate interactions; (3) the ability to modulate cell migration, e.g., abnormal migration, e.g., metastasis of tumor cells; (4) the ability to modulate cell differentiation (e.g., differentiation of cells of the kidney, liver, heart, testis,
  • the TANGO 130 proteins of the present invention can be operably linked to a non-TANGO 130 polypeptide (e.g., heterologous amino acid sequences) to form TANGO 130 fusion proteins.
  • the invention further features antibodies that specifically bind TANGO 130 proteins, such as monoclonal or polyclonal antibodies.
  • the TANGO 130 proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.
  • the present invention provides a method for detecting the presence of TANGO 130 activity or expression in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of TANGO 130 activity such that the presence of TANGO 130 activity is detected in the biological sample.
  • the invention provides a method for modulating TANGO 130 activity comprising contacting a cell with an agent that modulates (inhibits or stimulates) TANGO 130 activity or expression such that TANGO 130 activity or expression in the cell is modulated.
  • the agent is an antibody that specifically binds to TANGO 130 protein.
  • the agent modulates expression of TANGO 130 by modulating transcription of a TANGO 130 gene, splicing of a TANGO 130 mRNA, or translation of a TANGO 130 mRNA.
  • the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of the TANGO 130 mRNA or the TANGO 130 gene.
  • the methods of the present invention are used to treat a subject having a disorder characterized by aberrant TANGO 130 protein activity or nucleic acid expression by administering an agent which is a TANGO 130 modulator to the subject.
  • the TANGO 130 modulator is a TANGO 130 protein.
  • the TANGO 130 modulator is a TANGO 130 nucleic acid molecule.
  • the TANGO 130 modulator is a peptide, peptidomimetic, or other small molecule.
  • the disorder characterized by aberrant TANGO 130 protein or nucleic acid expression is marked by abnormal cellular growth, e.g., abnormal growth of the kidney, liver (e.g., regenerative disorders, liver atrophy, necrosis, cirrhosis or fibrosis), heart (e.g., cardiac damage following radiation therapy, hypertension, atherosclerosis or ischemic heart disease), central nervous system (e.g., motor neuron disease, multiple sclerosis, or degenerative disorders of the brain, e.g., Parkinson's or Alzheimer's diseases), cartilage (e.g., achondroplasia or osteoarthritis), skeleton (e.g., osteoporosis or fibrous dysplasia), skeletal muscle (e.g., fibromatoses), skin (e.g., psoriasis), immune system (e.g., inflammation or autoimmune disease) or testis (testicular atrophy).
  • abnormal cellular growth e.g., abnormal growth of the kidney, liver (e.
  • disorders characterized by abnormal cell growth also include cancer, e.g., primary or metastatic cancer of, e.g., the kidney, liver (e.g., hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, or metastatic tumors of the liver), heart (e.g., primary sarcomas, e.g., lymphomas, or metastasis from cervical carcinoma), central nervous system (e.g., metastatic tumors (e.g., from lung, breast, kidney or the gastrointestinal tract, or metastatic tumors from melanoma), primary lymphomas, gliomas (e.g., astrocytomas or glioblastoma multiforme), or neuroblastomas), cartilage, skeleton (e.g., osteosarcoma, chondrosarcoma or Ewing's sarcoma), skeletal muscle (e.g., primary skeletal muscle lymphoma or rhabdom
  • disorders characterized by aberrant TANGO 130 protein activity or nucleic acid expression may be marked by abnormal development, e.g., developmental disorders or abnormalities of the kidney, liver, heart, central nervous system, cartilage, skeleton, skeletal muscle, skin, immune system or testis, e.g., metabolic disorders (e.g., obesity, Gaucher's disease, or hemochromatosis), cardiac abnormalities (e.g., cardiac hypertrophy, cardiomyopathies, restenosis or congenital heart disease), neurodevelopmental disorders (e.g., developmental malformations of the central nervous system), chondrogenic disorders, skeletal abnormalities (e.g., Paget's disease), muscular atrophic or dystrophic disorders (e.g., congenital myopathy or muscular dystrophy), skin disorders, or sexual differentiation or dysfunction disorders (e.g., spermatogenesis, male infertility, undescended testis, gonadal dysgenesis, or androgen insensitivity syndrome).
  • metabolic disorders e.g., obesity, Gaucher
  • the present invention also provides a diagnostic assay for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a TANGO 130 protein; (ii) mis-regulation of a gene encoding a TANGO 130 protein; and (iii) aberrant post-translational modification of a TANGO 130 protein, wherein a wild-type form of the gene encodes a protein with a TANGO 130 activity.
  • the invention provides a method for identifying a compound that binds to or modulates the activity of a TANGO 130 protein.
  • such methods entail measuring a biological activity of a TANGO 130 protein in the presence and absence of a test compound and identifying those compounds which alter the activity of the TANGO 130 protein.
  • the invention also features methods for identifying a compound which modulates the expression of TANGO 130 by measuring the expression of TANGO 130 in the presence and absence of a compound.
  • Figures 1A-1D depict the cDNA sequence (SEQ ID NO:l) and predicted amino acid sequence (SEQ ID NO:3) of mouse TANGO 130.
  • the open reading frame of SEQ ID NO:l extends from nucleotide 24 to nucleotide 2165 (SEQ ID NO:2).
  • FIG. 2 is a hydropathy plot of mouse TANGO 130.
  • the region encoding the signal sequence is indicated (“sp"), as are the position of cysteines ("cys”; small triangles immediately below the plot).
  • sp region encoding the signal sequence
  • cysteines cysteines
  • MIA CD-RAP
  • Relative hydrophobicity is shown below the line marked "0”
  • relative hydrophilicity is shown above the line marked "0”.
  • Figures 3A-3B depict the cDNA sequence (SEQ ID NO:7) and predicted amino acid sequence (SEQ ID NO:9) of human TANGO 130.
  • the open reading frame of SEQ ID NO:7 extends from nucleotide 34 to nucleotide 1263 (SEQ ID NO:8).
  • Figure 4 is a hydropathy plot of human TANGO 130.
  • the region encoding the signal sequence is indicated (“sp"), as are the position of cysteines ("cys”; small triangles immediately below the plot).
  • MIA MIA homology domain
  • Relative hydrophobicity is shown below the line marked “0”
  • relative hydrophilicity is shown above the line marked "0”.
  • Figure 5 depicts an amino acid alignment of the MIA homology domain of human and mouse TANGO 130 ("Human T130 MIA", SEQ ID NO: 1
  • the present invention is based on the discovery of cDNA molecules encoding mouse and human TANGO 130 which share homology to MIA.
  • a nucleotide sequence encoding a mouse TANGO 130 protein is shown in
  • Figures 1A-1D (SEQ ID NO:l; SEQ ID NO:2 includes the open reading frame only).
  • a predicted amino acid sequence of mouse TANGO 130 protein is also shown in Figures 1A-1D (SEQ ID NO:3).
  • the mouse TANGO 130 cDNA is approximately 2886 nucleotides long including untranslated regions and encodes a 714 amino acid protein having a molecular weight of approximately 78.5 kDa (excluding post-translational modifications).
  • the cDNA encodes a predicted amino terminal signal peptide sequence of approximately 24 amino acids (SEQ ID NO:5), the cleavage of which leaves an approximately 690 amino acid mature polypeptide (SEQ ID NO:4) with a molecular weight of approximately 75.9 kDa (excluding post-translational modifications).
  • SEQ ID NO:5 A plasmid containing nucleotides 1 to 1555 of murine TANGO 130 cDNA (with the cDNA insert name of "marnaMIA.mouse.5' ") was deposited with
  • a plasmid containing nucleotides 1264- 2886 of murine TANGO 130 cDNA was deposited with American Type Culture Collection (ATCC), Manassas, Virginia on and assigned Accession Number .
  • a plasmid containing nucleotides 1264- 2886 of murine TANGO 130 cDNA was deposited with American Type Culture Collection (ATCC), Manassas, Virginia on and assigned Accession Number .
  • a plasmid containing nucleotides 1264- 2886 of murine TANGO 130 cDNA was deposited with American Type Culture
  • a nucleotide sequence encoding a human TANGO 130 protein is shown in Figures 3A-3B (SEQ ID NO:7; SEQ ID NO:8 includes the open reading frame only).
  • a predicted amino acid sequence of human TANGO 130 protein is also shown in Figures 3A-3B (SEQ ID NO: 9).
  • the human TANGO 130 cDNA is approximately 1263 nucleotides long including untranslated regions and encodes a partial protein having a molecular weight of approximately 46.5 kDa (excluding post-translational modifications).
  • the sequence encodes a predicted amino terminal signal peptide sequence of approximately 23 amino acids (SEQ ID NO: 11), the cleavage of which leaves an approximately 387 amino acid mature polypeptide (SEQ ID NO: 10) with a molecular weight of approximately 44.0 kDa (excluding post-translational modifications).
  • a plasmid containing a cDNA encoding human TANGO 130 was deposited with American Type Culture Collection (ATCC), Manassas, Virginia on July 21, 1998 and assigned Accession Number 98823. These deposits will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. These deposits were made merely as a convenience for those of skill in the art and are not an admission that a deposit is required under 35 U.S.C. ⁇ 112.
  • TANGO 130 molecules which contain a signal sequence.
  • a signal sequence or signal peptide is a peptide containing approximately 20 to 25 amino acids which occurs at the extreme N-terminal end of secretory and integral membrane proteins.
  • Signal sequences typically contain large numbers of hydrophobic amino acid residues which serve to direct a protein containing such a sequence to a lipid bilayer.
  • the predicted signal sequences of human and mouse TANGO 130 for example, are strongly hydrophobic sequences of 23 and 24 amino acids, respectively, as shown in the TANGO 130 hydropathy plots ( Figures 4 and 2, respectively).
  • MIA homology domain contains a consensus sequence comprising preferably at least about 135 amino acids, more preferably at least about 130, 125, 120, 100, or 50 amino acids.
  • the consensus sequence derived from the alignment shown in Figure 5, is as follows:
  • the MIA homology domain of TANGO 130 comprises amino acids 1 to 125 of human and mouse TANGO 130 (SEQ ID NO:12 and SEQ ID NO:6, respectively). Amino acids 36 through 98 in particular show a high degree of identity between TANGO 130 and MIA/CD-RAP. Also of note is the conservation of four cysteines (underlined above) within the TANGO 130 proteins at amino acid positions 38, 43, 61 and 124 of SEQ ID NO:3 and SEQ ID NO:9. The four conserved cysteines are believed to form two intramolecular disulfide bonds and are likely important for maintaining the molecule as an active protein. The positions of these cysteines match those of human, mouse, rat and bovine MIA/CD-RAP.
  • TANGO 130 An approximately 7 kb TANGO 130 mRNA transcript is expressed at a moderate level in mouse liver, testis, heart and skeletal muscle. Lower levels of this transcript were observed in mouse brain. Another TANGO 130 transcript of approximately 1 kb was detected in mouse testis. Additionally, the approximately 7 kb size transcript of TANGO 130 was expressed throughout mouse embryonic development with the highest expression in day 7 embryo.
  • Mouse and human TANGO 130 are members of a family of molecules
  • TANGO 130 family having certain conserved structural and functional features.
  • family when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence identity as defined herein. Such family members can be naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin and a homologue of that protein of murine origin, as well as a second, distinct protein of human origin and a murine homologue of that protein. Members of a family may also have common functional characteristics.
  • a TANGO 130 protein includes a MIA homology domain having at least about 45%, preferably at least about 55%, and more preferably about 65%, 75%, 85%, 95%, or 98% amino acid sequence identity to the MIA homology domain of SEQ ID NO:6 or SEQ ID NO: 12.
  • Preferred TANGO 130 polypeptides of the present invention have an amino acid sequence sufficiently identical to the MIA homology domain of SEQ ID NO:6 or SEQ ID NO: 12.
  • amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity.
  • amino acid or nucleotide sequences which contain a common structural domain having about 45% identity, preferably 55% identity, and more preferably 65%, 75%, 85%, 95%, or 98% identity are defined herein as sufficiently identical.
  • TANGO 130 activity refers to an activity exerted by a TANGO 130 protein, polypeptide or nucleic acid molecule on a TANGO 130 responsive cell as determined in vivo, or in vitro, according to standard techniques.
  • a TANGO 130 activity can be a direct activity, such as an association with or an enzymatic activity on a second protein or an indirect activity, such as a cellular signaling activity mediated by interaction of the TANGO 130 protein with a second protein.
  • a TANGO 130 activity includes at least one or more of the following activities: (i) the ability to interact with proteins in the TANGO 130 signaling pathway; (ii) the ability to interact with a TANGO 130 receptor; and (iii) the ability to interact with an intracellular target protein.
  • Other activities include: (1) the ability to modulate, e.g., inhibit, cell proliferation (e.g., proliferation of cells of the kidney, liver, heart, testis, immune system, skin, cartilage, skeleton, skeletal muscle and central nervous system), e.g., abnormal cell proliferation, e.g., malignant cell proliferation, e.g., malignant proliferation of epithelial cells (e.g., carcinomas, e.g., melanomas), malignant proliferation of mesenchymal cells (e.g., sarcomas, e.g., chondrosarcomas, glioblastomas); (2) the ability to modulate cell-cell interactions, e.g., cell adhesion, or cell-substrate interactions; (3) the ability to modulate cell migration, e.g., abnormal migration, e.g., metastasis of tumor cells; (4) the ability to modulate cell differentiation (e.g., differentiation of cells of the kidney, liver, heart, testis,
  • TANGO 130 molecules of the invention can be assayed for their ability to modulate growth, e.g., proliferation, or metabolism of cells. Such activities can be detected by, for example, measurement of 3 H-thymidine uptake in response to exposure of cells to TANGO 130 molecules (as described in Canadian Patent Application Number 2,167,693 at page 28). Briefly, cells are treated with a TANGO 130 molecule for several days and then pulsed with 3 H-thymidine. Radioactivity incorporated into DNA, as measured by, e.g., scintillation counting of the TCA-precipitated DNA, is indicative of DNA synthesis and cellular proliferation. In addition, TANGO 130 molecules of the invention can be assayed for their ability to modulate tumor cell transforming potential.
  • tumor colony formation can be measured in soft agar (e.g., by transfecting tumor cells with TANGO 130 DNA molecules of the invention, plating in soft agar and monitoring for growth over several weeks).
  • invasiveness of tumor cells can be measured, for example, as the ability to modulate tumor chemotaxis to an attractant through a Costar Boyden chamber (see Canadian Patent Application Number 2,167,693 at page 30; Albini et al. (1987) Cancer Res. 47:3239).
  • TANGO 130 molecules to modulate invasiveness can also be measured in vivo, for example, by monitoring tumor growth in mice injected with cells, e.g., transformed cells, that have been modified by transfection with a TANGO 130 DNA molecule to express a TANGO 130 protein.
  • TANGO 130 expression may alter the ability of tumorigenic cells to invade tissues and form tumors in mice.
  • TANGO 130 molecules of the invention are examined microscopically before and after treatment with TANGO 130 molecules of the invention.
  • TANGO 130 treatment of eukaryotic cells e.g., metastatic tumor cells or transformed cell lines, may result in observable changes in cell morphology and adhesion, e.g., from flat- shaped and tightly adherent to rounded and less adherent.
  • TANGO 130 molecules of the invention to modulate cell differentiation and proliferation includes the use of TANGO 130 molecules to modulate the regenerative capacity of tissues, e.g., of kidney, liver, heart, testis, skeleton, cartilage, skin, brain, immune cells or skeletal muscle.
  • tissues e.g., of kidney, liver, heart, testis, skeleton, cartilage, skin, brain, immune cells or skeletal muscle.
  • assays are known in the art for examining regenerative potential of tissues.
  • an ischemic/reperfusion model can be used in kidney, in which the kidney's capacity for renewal is measured following injury (see Ichimura et al. (1998) J. Biol. Chem. 273:4135).
  • Tissue injury and regeneration, with and without pre-treatment with TANGO 130 molecules can be monitored by immunohistochemistry using markers for regeneration, e.g., vimentin detected using anti-vimentin monoclonal antibodies in sectioned tissue.
  • another embodiment of the invention features isolated TANGO 130 proteins and polypeptides having a TANGO 130 activity.
  • TANGO 130 proteins and polypeptides having a TANGO 130 activity are described in further detail in the following subsections.
  • nucleic acid molecules that encode TANGO 130 proteins or biologically active portions thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify TANGO 130-encoding nucleic acids (e.g., TANGO 130 mRNA) and fragments for use as PCR primers for the amplification or mutation of TANGO 130 nucleic acid molecules.
  • nucleic acid molecule is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs.
  • the nucleic acid molecule can be single- stranded or double-stranded, but preferably is double-stranded DNA.
  • An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid.
  • an "isolated" nucleic acid is free of sequences (preferably protein encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived.
  • the isolated TANGO 130 nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived.
  • an "isolated" nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • a nucleic acid molecule of the present invention e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, the cDNA of
  • ATCC ATCC , or a complement of any of these nucleotide sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the coding or non- coding nucleic acid sequences of SEQ ID NO:l, SEQ ID NO:7, the cDNA of SEQ ID NO:l, SEQ ID NO:7, the cDNA of SEQ ID NO:l, SEQ ID NO:7, the cDNA of SEQ ID NO:l, SEQ ID NO:7, the cDNA of SEQ ID NO:l, SEQ ID NO:7, the cDNA of
  • ATCC 98823 the cDNA of ATCC as a hybridization probe, TANGO
  • nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • a nucleic acid molecule of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.
  • oligonucleotides corresponding to TANGO 130 nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.
  • an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO: 1 , SEQ ID NO:7, the cDNA of
  • nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence to thereby form a stable duplex.
  • the nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding TANGO 130, for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of TANGO 130.
  • the nucleotide sequences determined from the cloning of the mouse and human TANGO 130 genes allow for the generation of probes and primers designed for use in identifying and/or cloning TANGO 130 homologues in other cell types, e.g., from other tissues, as well as TANGO 130 homologues from other mammals.
  • the probe/primer typically comprises substantially purified oligonucleotide.
  • the oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350 or 400 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:l,
  • SEQ ID NO:7 the cDNA of ATCC 98823, or the cDNA of ATCC ; or of a naturally occurring mutant of SEQ ID NO:l, SEQ ID NO:7, the cDNA of ATCC 98823, or the cDNA of ATCC .
  • Probes based on the human TANGO 130 nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or identical proteins.
  • the probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor.
  • Such probes can be used as part of a diagnostic test kit for identifying cells or tissues which mis-express a TANGO 130 protein, such as by measuring levels of a TANGO 130-encoding nucleic acid in a sample of cells from a subject, e.g., detecting TANGO 130 mRNA levels or determining whether a genomic TANGO 130 gene has been mutated or deleted.
  • TANGO 130 can be prepared by isolating a portion of SEQ ID NO:l, SEQ ID NO:7, the nucleotide sequence of the cDNA of ATCC 98823, or the nucleotide sequence of the cDNA of ATCC , which encodes a polypeptide having a TANGO 130 biological activity, expressing the encoded portion of TANGO 130 protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of TANGO 130.
  • a nucleic acid fragment encoding a biologically active portion of TANGO 130 includes a MIA homology domain, e.g., SEQ ID NO:6 or SEQ ID NO: 12.
  • the invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, or the cDNA of ATCC due to degeneracy of the genetic code and thus encode the same TANGO 130 protein as that encoded by the nucleotide sequence shown in SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, or the cDNA of ATCC .
  • DNA sequence polymorphisms that lead to changes in the amino acid sequences of TANGO 130 may exist within a population (e.g., the human population). Such genetic polymorphism in the TANGO 130 gene may exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus.
  • the terms "gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a TANGO 130 protein, preferably a mammalian TANGO 130 protein.
  • allelic variant refers to a nucleotide sequence which occurs at a TANGO 130 locus or to a polypeptide encoded by the nucleotide sequence.
  • Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the TANGO 130 gene.
  • Alternative alleles can be identified by sequencing the gene of interest in a number of different individuals. This can be readily carried out by using hybridization probes to identify the same genetic locus in a variety of individuals. Any and all such nucleotide variations and resulting amino acid polymorphisms or variations in TANGO 130 that are the result of natural allelic variation and that do not alter the functional activity of TANGO 130 are intended to be within the scope of the invention.
  • nucleic acid molecules encoding TANGO 130 proteins from other species which have a nucleotide sequence which differs from that of a human TANGO 130, are intended to be within the scope of the invention.
  • Nucleic acid molecules corresponding to natural allelic variants and homologues of the TANGO 130 cDNA of the invention can be isolated based on their identity to the human TANGO 130 nucleic acids disclosed herein using the mouse or human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.
  • alternate forms of TANGO 130 e.g., membrane-bound forms, can be isolated based on their ability to bind a TANGO 130 hybridization probe.
  • an isolated nucleic acid molecule of the invention is at least 500 (550, 600, 650, 700, 800, 900, 1000, 1250, 1500, 1750, 2000, 2500, or 3000) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:l, SEQ ID NO:7, the cDNA of ATCC 98823, the cDNA of ATCC , or a complement thereof.
  • hybridizes under stringent conditions is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other.
  • stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.
  • a preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45(C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65(C.
  • an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, the cDNA of
  • ATCC corresponds to a naturally-occurring nucleic acid molecule.
  • a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).
  • allelic variants of the TANGO 130 sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, or the cDNA of ATCC , thereby leading to changes in the amino acid sequence of the encoded TANGO 130 protein, without altering the biological activity of the TANGO 130 protein.
  • non-essential amino acid residue is a residue that can be altered from the wild-type sequence of TANGO 130 (e.g., the sequences of SEQ ID NO:3 or SEQ ID NO:9) without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity.
  • amino acid residues that are not conserved or only semi-conserved among TANGO 130 of various species may be non-essential for activity and thus would be likely targets for alteration.
  • amino acid residues that are conserved among the TANGO 130 proteins of various species may be essential for activity and thus would not be likely targets for alteration.
  • preferred TANGO 130 proteins of the present invention contain at least one MIA homology domain, as described herein (see Figure 5). Within this domain are a number of amino acid residues which are conserved between human and mouse MIA, bovine CD-RAP, and human and mouse TANGO 130.
  • the sequence glutamate-cysteine-serine (ECS) is conserved; at approximately amino acids 59 to 63 of SEQ ID NO:9 and SEQ ID NO:3, the sequence proline-aspartate-cysteine-arginine- phenylalanine (PDCRF) is conserved; and at approximately amino acids 95 to 98 of SEQ ID NO:9 and SEQ ID NO:3, the sequence glycine-tyrosine-
  • SUBSTTTUTE SHEET (RULE 26) phenylalanine-proline (GYFP) is conserved. These conserved amino acids, for example, are likely to be essential for activity and thus would not be likely targets for alteration. Additionally, preferred TANGO 130 proteins of the present invention contain approximately four cysteine residues in positions corresponding to those shown in Figure 5. Thus, these cysteines are likely to be essential and would not be likely targets for alteration.
  • nucleic acid molecules encoding TANGO 130 proteins that contain changes in amino acid residues that are not essential for activity. Such TANGO 130 proteins differ in amino acid sequence from SEQ ID NO: 3 and SEQ ID NO: 9 yet retain biological activity.
  • the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 45% identical, 55%, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequences of SEQ ID NO:3 or SEQ ID NO:9.
  • An isolated nucleic acid molecule encoding a TANGO 130 protein having a sequence which differs from that of SEQ ID NO:3 or SEQ ID NO:9 can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, the cDNA of ATCC 98823, or the cDNA of ATCC such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues.
  • a "conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspartic acid, glutamic acid
  • uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
  • nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
  • beta- branched side chains e.g., threonine, valine, isoleucine
  • aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
  • a predicted nonessential amino acid residue in TANGO 130 is preferably replaced with another amino acid residue from the same side chain family.
  • mutations can be introduced randomly along all or part of a TANGO 130 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for TANGO 130 biological activity to identify mutants that retain activity.
  • the encoded protein can be expressed recombinantly and the activity of the protein can be determined.
  • a mutant TANGO 130 protein can be assayed for the activities described herein.
  • the present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid.
  • the antisense nucleic acid can be complementary to an entire TANGO 130 coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame).
  • An antisense nucleic acid molecule can be antisense to a noncoding region of the coding strand of a nucleotide sequence encoding TANGO 130.
  • the noncoding regions (“5 1 and 3' untranslated regions") are the 5' and 3' sequences which flank the coding region and are not translated into amino acids.
  • antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing.
  • the antisense nucleic acid molecule can be complementary to the entire coding region of TANGO 130 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of TANGO 130 mRNA.
  • the antisense oligonucleotide can be complementary to the region surrounding the translation start site of TANGO 130 mRNA, e.g., an oligonucleotide having the sequence corresponding to nucleotides 18 to 36, nucleotides 21 to 50, or nucleotides 20 to 66 of SEQ ID NO:l, or corresponding to nucleotides 31 to 49, nucleotides 30 to 76, or nucleotides 25 to 56 of SEQ ID NO:7.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • an antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
  • modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5- iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5- (carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1- methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3- methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5- methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D- mannosylqueosine, 5'-
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).
  • the antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a TANGO 130 protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation.
  • the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.
  • An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site.
  • antisense nucleic acid molecules can be modified to target selected cells and then administered systemically.
  • antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens.
  • the antisense nucleic acid molecules can also be delivered to cells using the vectors described herein.
  • vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
  • An antisense nucleic acid molecule of the invention can be an - anomeric nucleic acid molecule.
  • An ⁇ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids Res. 15:6625).
  • the antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327).
  • Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region.
  • ribozymes e.g., hammerhead ribozymes (described in Haselhoff and Geriach (1988) Nature 334:585)
  • ribozymes can be used to catalytically cleave TANGO 130 mRNA transcripts to thereby inhibit translation of TANGO 130 mRNA.
  • TANGO 130-encoding nucleic acid can be designed based upon the nucleotide sequence of a TANGO 130 cDNA disclosed herein (e.g., SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:7, or SEQ ID NO:8).
  • a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a TANGO 130-encoding mRNA. See, e.g., Cech et al. U.S. Patent No. 4,987,071; and Cech et al. U.S. Patent No. 5,116,742.
  • TANGO 130 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak (1993) Science 261:1411.
  • the invention also encompasses nucleic acid molecules which form triple helical structures.
  • TANGO 130 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the TANGO 130 (e.g., the TANGO 130 promoter and/or enhancers) to form triple helical structures that prevent transcription of the TANGO 130 gene in target cells.
  • nucleotide sequences complementary to the regulatory region of the TANGO 130 e.g., the TANGO 130 promoter and/or enhancers
  • the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule.
  • the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorganic & Medicinal Chemistry 4:5).
  • the terms "peptide nucleic acids” or "PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
  • PNAs The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
  • the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) supra; Perry-O'Keefe et al. (1996) Proc. Natl Acad. Sci. USA 93:14670.
  • PNAs of TANGO 130 can be used in therapeutic and diagnostic applications.
  • PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication.
  • PNAs of TANGO 130 can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., SI nucleases (Hyrup (1996), supra) or as probes or primers for DNA sequence and hybridization (Hyrup (1996), supra; Perry-O'Keefe et al. (1996), supra).
  • PNAs of TANGO 130 can be modified, e.g., to enhance their stability, specificity or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.
  • One aspect of the invention pertains to isolated TANGO 130 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-TANGO 130 antibodies.
  • native TANGO 130 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques.
  • TANGO 130 proteins are produced by recombinant DNA techniques.
  • a TANGO 130 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.
  • an “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the TANGO 130 protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • the language “substantially free of cellular material” includes preparations of TANGO 130 protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.
  • TANGO 130 protein that is substantially free of cellular material includes preparations of TANGO 130 protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of non-TANGO 130 protein (also referred to herein as a "contaminating protein").
  • TANGO 130 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation.
  • culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation.
  • TANGO 130 protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of TANGO 130 protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or non-TANGO 130 chemicals.
  • Biologically active portions of a TANGO 130 protein include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the TANGO 130 protein (e.g., the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:9), which include fewer amino acids than the full length TANGO 130 proteins, and exhibit at least one activity of a TANGO 130 protein.
  • biologically active portions comprise a domain or motif with at least one activity of the TANGO 130 protein.
  • a biologically active portion of a TANGO 130 protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.
  • Preferred biologically active polypeptides include one or more identified TANGO 130 structural domains, e.g., the MIA homology domain (e.g., SEQ ID NO:6 or SEQ ID NO: 12).
  • biologically active portions in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native TANGO 130 protein.
  • Preferred TANGO 130 protein has the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:9.
  • Other useful TANGO 130 proteins are substantially identical to SEQ ID NO:3 or SEQ ID NO:9 and retain the functional activity of the protein of SEQ ID NO:3 or SEQ ID NO:9 yet differ in amino acid sequence due to natural allelic variation or mutagenesis.
  • such TANGO 130 proteins and polypeptides possess at least one biological activity described herein.
  • a useful TANGO 130 protein is a protein which includes an amino acid sequence at least about 45%, preferably 55%, 65%, 75%, 85%, 95%, or 99% identical to the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:9 and retains the functional activity of the TANGO 130 proteins of SEQ ID NO:3 or SEQ ID NO:9.
  • the TANGO 130 protein is a protein having an amino acid sequence 55%, 65%, 75%), 85%, 95%, or 98% identical to the TANGO 130 MIA homology domain (SEQ ID NO:6 or SEQ ID NO: 12).
  • the TANGO 130 protein retains a functional activity of the TANGO 130 protein of SEQ ID NO: 3 or SEQ ID NO:9.
  • the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence).
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
  • a preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, modified as in Karlin and Altschul (1993) Proc Natl Acad. Sci. USA 90:5873.
  • Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403.
  • Gapped BLAST can be utilized as described in Altschul et al. (1997) Nucleic Acids Res. 25:3389.
  • PSI-BLAST can be used to perform an iterated search which detects distant relationships between molecules. Altshcul et al., (1997), supra.
  • the default parameters of the respective programs e.g., XBLAST and NBLAST
  • the percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.
  • the invention also provides TANGO 130 chimeric or fusion proteins.
  • a TANGO 130 "chimeric protein” or “fusion protein” comprises a TANGO 130 polypeptide operably linked to a non-TANGO 130 polypeptide.
  • a "TANGO 130 polypeptide” refers to a polypeptide having an amino acid sequence corresponding to TANGO 130
  • a “non-TANGO 130 polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially identical to the TANGO 130 protein, e.g., a protein which is different from the TANGO 130 protein and which is derived from the same or a different organism.
  • the TANGO 130 polypeptide can correspond to all or a portion of a TANGO 130 protein, preferably at least one biologically active portion of a TANGO 130 protein.
  • the term "operably linked" is intended to indicate that the TANGO 130 polypeptide and the non-TANGO 130 polypeptide are fused in-frame to each other.
  • the non- TANGO 130 polypeptide can be fused to the N-terminus or C-terminus of the TANGO 130 polypeptide.
  • One useful fusion protein is a GST-TANGO 130 fusion protein in which the TANGO 130 sequences are fused to the C-terminus of the GST sequences.
  • the fusion protein can facilitate the purification of recombinant TANGO 130.
  • the fusion protein is a TANGO 130 protein containing a heterologous signal sequence at its N-terminus.
  • the native TANGO 130 signal sequence i.e., about amino acids 1 to 24 of SEQ ID NO:3 or about amino acids 1 to 23 of SEQ ID NO:9 can be removed and replaced with a signal sequence from another protein.
  • expression and/or secretion of TANGO 130 can be increased through use of a heterologous signal sequence.
  • the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Current Protocols in Molecular Biology, Ausubel et al., eds. (1992) John Wiley & Sons).
  • Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California).
  • useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., supra) and the protein A secretory signal (Pharmacia Biotech, Piscataway, New Jersey).
  • the fusion protein is a TANGO 130- immunoglobulin fusion protein in which all or part of TANGO 130 is fused to sequences derived from a member of the immunoglobulin protein family.
  • the TANGO 130-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a secreted TANGO 130 and a TANGO 130 receptor on the surface of a cell, to thereby suppress TANGO 130-mediated signal transduction in vivo.
  • the TANGO 130-immunoglobulin fusion proteins can be used to affect the bioavailability of a TANGO 130 cognate receptor.
  • Inhibition of the TANGO 130/TANGO 130 receptor interaction may be useful therapeutically, both for treating prohferative and differentiative disorders and for modulating (e.g., promoting or inhibiting) cell survival.
  • the TANGO 130-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-TANGO 130 antibodies in a subject, to purify TANGO 130 receptors and in screening assays to identify molecules which inhibit the interaction of TANGO 130 with a TANGO 130 receptor.
  • a TANGO 130 chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques.
  • DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation.
  • the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.
  • PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel et al., supra).
  • anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence
  • many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide).
  • An TANGO 130- encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in- frame to the TANGO 130 protein.
  • the TANGO 130 signal sequences er se can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest.
  • Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events.
  • Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway.
  • the invention pertains to the described polypeptides having signal sequences, as well as to the signal sequences themselves and to the polypeptides in the absence of the signal sequence (i.e., the cleavage products; SEQ ID NO:4 and SEQ ID NO: 10).
  • a nucleic acid sequence encoding a signal sequence of the invention can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate.
  • the signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved.
  • the protein can then be readily purified from the extracellular medium by art recognized methods.
  • the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.
  • the signal sequences of the present invention can be used to identify regulatory sequences, e.g., promoters, enhancers, repressors. Since signal sequences are the most amino-terminal sequences of a peptide, it is expected that the nucleic acids which flank the signal sequence on its amino-terminal side will be regulatory sequences which affect transcription. Thus, a nucleotide sequence which encodes all or a portion of a signal sequence can be used as a probe to identify and isolate signal sequences and their flanking regions, and these flanking regions can be used to identify regulatory elements therein.
  • regulatory sequences e.g., promoters, enhancers, repressors.
  • the present invention also pertains to variants of the TANGO 130 proteins (i.e., proteins having a sequence which differs from that of the TANGO 130 amino acid sequence). Such variants can function as either TANGO 130 agonists (mimetics) or as TANGO 130 antagonists. Variants of the TANGO 130 protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the TANGO 130 protein. An agonist of the TANGO 130 protein can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the TANGO 130 protein.
  • An antagonist of the TANGO 130 protein can inhibit one or more of the activities of the naturally occurring form of the TANGO 130 protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the TANGO 130 protein.
  • specific biological effects can be elicited by treatment with a variant of limited function.
  • Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the TANGO 130 proteins.
  • Variants of the TANGO 130 protein which function as either TANGO 130 agonists (mimetics) or as TANGO 130 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the TANGO 130 protein for TANGO 130 protein agonist or antagonist activity.
  • a variegated library of TANGO 130 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library.
  • a variegated library of TANGO 130 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential TANGO 130 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of TANGO 130 sequences therein.
  • methods which can be used to produce libraries of potential TANGO 130 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector.
  • degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential TANGO 130 sequences.
  • Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acid Res. 11 :477).
  • libraries of fragments of the TANGO 130 protein coding sequence can be used to generate a variegated population of TANGO 130 fragments for screening and subsequent selection of variants of a TANGO 130 protein.
  • a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a TANGO 130 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1 nuclease, and ligating the resulting fragment library into an expression vector.
  • an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the TANGO 130 protein.
  • REM Recursive ensemble mutagenesis
  • An isolated TANGO 130 protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind TANGO 130 using standard techniques for polyclonal and monoclonal antibody preparation.
  • the full-length TANGO 130 protein can be used or, alternatively, the invention provides antigenic peptide fragments of TANGO 130 for use as immunogens.
  • the antigenic peptide of TANGO 130 comprises at least 8 (preferably 10, 15, 20, or 30) amino acid residues of the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:9 and encompasses an epitope of TANGO 130 such that an antibody raised against the peptide forms a specific immune complex with TANGO 130.
  • Preferred epitopes encompassed by the antigenic peptide are regions of TANGO 130 that are located on the surface of the protein, e.g., hydrophilic regions.
  • a hydrophobicity analysis of the mouse TANGO 130 protein sequence indicates that the regions between, e.g., amino acids 152 and 215, between amino acids 391 and 436, and between amino acids 570 and 622 of SEQ ID NO:3 are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production.
  • hydrophobicity analysis of the human TANGO 130 protein sequence indicates that the regions between, e.g., amino acids 159 and 224, between amino acids 242 and 260, and between amino acids 335 and 363 of SEQ ID NO:9 are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production.
  • a TANGO 130 immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen.
  • An appropriate immunogenic preparation can contain, for example, recombinantly expressed TANGO 130 protein or a chemically synthesized TANGO 130 polypeptide.
  • the preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar irnmunostimulatory agent. Immunization of a suitable subject with an immunogenic TANGO 130 preparation induces a polyclonal anti-TANGO 130 antibody response.
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as TANGO 130.
  • a molecule which specifically binds to TANGO 130 is a molecule which binds TANGO 130, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains TANGO 130.
  • immunologically active portions of immunoglobulin molecules include F(ab) and F(ab') 2 fragments which can be generated by treating the antibody with an enzyme such as pepsin.
  • the invention provides polyclonal and monoclonal antibodies that bind TANGO 130.
  • a monoclonal antibody composition thus typically displays a single binding affinity for a particular TANGO 130 protein with which it immunoreacts.
  • Polyclonal anti-TANGO 130 antibodies can be prepared as described above by immunizing a suitable subject with a TANGO 130 immunogen.
  • the anti-TANGO 130 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized TANGO 130.
  • ELISA enzyme linked immunosorbent assay
  • the antibody molecules directed against TANGO 130 can be isolated from a mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction.
  • antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
  • standard techniques such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques.
  • hybridomas The technology for producing hybridomas is well known (see generally Current Protocols in Immunology (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, NY). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a TANGO 130 immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds TANGO 130.
  • lymphocytes typically splenocytes
  • the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes.
  • murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line, e.g., a myeloma cell line that is sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium").
  • any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NSl/l-Ag4-l, P3-x63- Ag8.653 or Sp2/O-Agl4 myeloma lines. These myeloma lines are available from ATCC.
  • HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG").
  • Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed).
  • Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind TANGO 130, e.g., using a standard ELISA assay.
  • a monoclonal anti-TANGO 130 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with TANGO 130 to thereby isolate immunoglobulin library members that bind TANGO 130.
  • Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP( Phage Display Kit, Catalog No. 240612).
  • examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) BioTechniques 9:1370; Hay et al. (1992) Hum.
  • recombinant anti-TANGO 130 antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
  • Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No.
  • Fully human antibodies are particularly desirable for therapeutic treatment of human patients.
  • Such antibodies can be produced using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chain genes, but which can express human heavy and light chain genes.
  • the transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of TANGO 130.
  • Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology.
  • the human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies.
  • Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection.”
  • a selected non-human monoclonal antibody e.g., a murine antibody, is used to guide the selection of a completely human antibody recognizing the same epitope.
  • a non-human monoclonal antibody which binds a selected antigen (epitope), e.g., an antibody which inhibits TANGO 130 activity, is identified.
  • the heavy chain and the light chain of the non-human antibody are cloned and used to create phage display Fab fragments.
  • the heavy chain gene can be cloned into a plasmid vector so that the heavy chain can be secreted from bacteria.
  • the light chain gene can be cloned into a phage coat protein gene so that the light chain can be expressed on the surface of phage.
  • a repertoire (random collection) of human light chains fused to phage is used to infect the bacteria which express the non-human heavy chain.
  • the resulting progeny phage display hybrid antibodies (human light chain/non-human heavy chain).
  • the selected antigen is used in a panning screen to select phage which bind the selected antigen. Several rounds of selection may be required to identify such phage.
  • human light chain genes are isolated from the selected phage which bind the selected antigen. These selected human light chain genes are then used to guide the selection of human heavy chain genes as follows.
  • the selected human light chain genes are inserted into vectors for expression by bacteria. Bacteria expressing the selected human light chains are infected with a repertoire of human heavy chains fused to phage.
  • the resulting progeny phage display human antibodies (human light chain/human heavy chain).
  • the selected antigen is used in a panning screen to select phage which bind the selected antigen.
  • the phage selected in this step display a completely human antibody which recognizes the same epitope recognized by the original selected, non-human monoclonal antibody.
  • the genes encoding both the heavy and light chains are readily isolated and can be further manipulated for production of human antibody. This technology is described by Jespers et al. (1994) Biotechnology 12:899.
  • An anti-TANGO 130 antibody e.g., monoclonal antibody
  • An anti-TANGO 130 antibody can facilitate the purification of natural TANGO 130 from cells and of recombinantly produced TANGO 130 expressed in host cells. Moreover, an anti-TANGO 130 antibody can be used to detect TANGO 130 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the TANGO 130 protein. Anti-TANGO 130 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, (- galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • bioluminescent materials include luciferase, luciferin, and aequorin, and
  • suitable radioactive material include 125 1, 131 1, 35 S or 3 H.
  • vectors preferably expression vectors, containing a nucleic acid encoding TANGO 130 (or a portion thereof).
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector is another type of vector, wherein additional DNA segments can be ligated into the viral genome.
  • vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors).
  • the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno- associated viruses), which serve equivalent functions.
  • the recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell.
  • the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed.
  • operably linked is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).
  • regulatory sequence is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990).
  • Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
  • the expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., TANGO 130 proteins, mutant forms of TANGO 130, fusion proteins, etc.).
  • the recombinant expression vectors of the invention can be designed for expression of TANGO 130 in prokaryotic or eukaryotic cells, e.g., bacterial cells such as E. coli, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, supra.
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein.
  • Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
  • enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
  • Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • GST glutathione S-transferase
  • maltose E binding protein or protein A, respectively
  • Suitable inducible non- fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301) and pET l id (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 60-89).
  • Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter.
  • Target gene expression from the pET l id vector relies on transcription from a T7 gnlO-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gnl). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident ( prophage harboring a T7 gnl gene under the transcriptional control of the lacUV 5 promoter.
  • One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, California (1990) 119-128).
  • Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 20:2111).
  • Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.
  • the TANGO 130 expression vector is a yeast expression vector.
  • yeast expression vectors for expression in yeast S. cerivisae include pYepSecl (Baldari et al. (1987) EMBO J. 6:229), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933), pJRY88 (Schultz et al. (1987) Gene 54:113), pYES2 (Invitrogen Corporation, San Diego, CA), and pPicZ (InVitrogen Corp, San Diego, CA).
  • TANGO 130 can be expressed in insect cells using baculovirus expression vectors.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith et al. (1983) Mol Cell Biol 3:2156) and the pVL series (Lucklow and Summers (1989) Virology 170:31).
  • a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector.
  • mammalian expression vectors include pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements.
  • promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.
  • suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al., supra.
  • the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
  • tissue-specific regulatory elements are known in the art.
  • suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729) and immunoglobulins (Banerji et al.
  • Neuron-specific promoters e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. USA 86:5473
  • pancreas-specific promoters e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166.
  • promoters Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374) and the (-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537).
  • the invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operably linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to TANGO 130 mRNA. Regulatory sequences operably linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA.
  • the antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.
  • a high efficiency regulatory region the activity of which can be determined by the cell type into which the vector is introduced.
  • host cell and "recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.
  • a host cell can be any prokaryotic or eukaryotic cell.
  • TANGO 130 protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.
  • Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques.
  • transformation and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, D ⁇ A ⁇ -dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals.
  • a gene that encodes a selectable marker (e.g., for resistance to antibiotics) is generally introduced into the host cells along with the gene of interest.
  • selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate.
  • Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding TANGO 130 or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).
  • a host cell of the invention such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) TANGO 130 protein.
  • the invention further provides methods for producing TANGO 130 protein using the host cells of the invention.
  • the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding TANGO 130 has been introduced) in a suitable medium such that TANGO 130 protein is produced.
  • the method further comprises isolating TANGO 130 from the medium or the host cell.
  • the host cells of the invention can also be used to produce nonhuman transgenic animals.
  • a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which TANGO 130-coding sequences have been introduced.
  • Such host cells can then be used to create non-human transgenic animals in which exogenous TANGO 130 sequences have been introduced into their genome or homologous recombinant animals in which endogenous TANGO 130 sequences have been altered.
  • Such animals are useful for studying the function and/or activity of TANGO 130 and for identifying and/or evaluating modulators of TANGO 130 activity.
  • a "transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene.
  • Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc.
  • a transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal.
  • an "homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous TANGO 130 gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.
  • a transgenic animal of the invention can be created by introducing TANGO 130-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal.
  • the TANGO 130 cDNA sequence e.g., that of (SEQ ID NO:l, SEQ ID NO:7, the cDNA of ATCC 98823, or the cDNA of ATCC
  • a nonhuman homologue of the human TANGO 130 gene such as the mouse TANGO 130 gene, can be used as a transgene.
  • Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene.
  • a tissue-specific regulatory sequence(s) can be operably linked to the TANGO 130 transgene to direct expression of TANGO 130 protein to particular cells.
  • a transgenic founder animal can be identified based upon the presence of the TANGO 130 transgene in its genome and/or expression of TANGO 130 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding TANGO 130 can further be bred to other transgenic animals carrying other transgenes.
  • a vector is prepared which contains at least a portion of a TANGO 130 gene (e.g., a human or a non-human homolog of the TANGO 130 gene, e.g., the murine TANGO 130 gene) into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the TANGO 130 gene.
  • the vector is designed such that, upon homologous recombination, the endogenous TANGO 130 gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).
  • the vector can be designed such that, upon homologous recombination, the endogenous TANGO 130 gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous TANGO 130 protein).
  • the altered portion of the TANGO 130 gene is flanked at its 5' and 3' ends by additional nucleic acid of the TANGO 130 gene to allow for homologous recombination to occur between the exogenous TANGO 130 gene carried by the vector and an endogenous TANGO 130 gene in an embryonic stem cell.
  • flanking TANGO 130 nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene.
  • flanking DNA both at the 5' and 3' ends
  • the vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced TANGO 130 gene has homologously recombined with the endogenous TANGO 130 gene are selected (see, e.g., Li et al. (1992) Cell 69:915).
  • the selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach,
  • a chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term.
  • Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene.
  • Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) Current Opinion in Bio/Technology 2:823-829 and in PCT Publication Nos.
  • transgenic non-human animals can be produced which contain selected systems which allow for regulated expression of the transgene.
  • One example of such a system is the cre/loxP recombinase system of bacteriophage PI.
  • cre/loxP recombinase system see, e.g., Lakso et al. (1992) Proc. Natl. Acad. Sci. USA 89:6232.
  • a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251 : 1351). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.
  • Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997)
  • a cell e.g., a somatic cell
  • the quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated.
  • the reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal.
  • the offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.
  • compositions suitable for administration typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetra-acetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
  • antibacterial agents such as benzyl alcohol or methyl parabens
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor EL( (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a TANGO 130 protein or anti-TANGO 130 antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • the active compound e.g., a TANGO 130 protein or anti-TANGO 130 antibody
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • active compound e.g., an antibody
  • a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment is sustained until a desired suppression of disease symptoms occurs.
  • other dosage regimens may be useful.
  • the progress of this therapy is easily monitored by conventional techniques and assays.
  • An exemplary dosing regimen is disclosed in WO 94/04188.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • the nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors.
  • Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Patent 5,328,470) or by stereotactic injection (see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91 :3054).
  • the pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
  • the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • the nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology); c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic).
  • a TANGO 130 protein interacts with other cellular proteins and can thus be used for (i) regulation of cellular proliferation; (ii) regulation of cellular differentiation; and (iii) regulation of cell survival.
  • the isolated nucleic acid molecules of the invention can be used to express TANGO 130 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect TANGO 130 mRNA (e.g., in a biological sample) or a genetic lesion in a TANGO 130 gene, and to modulate TANGO 130 activity.
  • the TANGO 130 proteins can be used to screen drugs or compounds which modulate the TANGO 130 activity or expression as well as to treat disorders characterized by insufficient or excessive production of TANGO 130 protein or production of TANGO 130 protein forms which have decreased or aberrant activity compared to TANGO 130 wild type protein.
  • the anti-TANGO 130 antibodies of the invention can be used to detect and isolate TANGO 130 proteins and modulate TANGO 130 activity.
  • This invention further pertains to novel agents identified by the above- described screening assays and uses thereof for treatments as described herein.
  • the invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to TANGO 130 proteins or have a stimulatory or inhibitory effect on, for example, TANGO 130 expression or TANGO 130 activity.
  • modulators i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to TANGO 130 proteins or have a stimulatory or inhibitory effect on, for example, TANGO 130 expression or TANGO 130 activity.
  • the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a membrane-bound form of a TANGO 130 protein or polypeptide or biologically active portion thereof.
  • the test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145).
  • TANGO 130 molecules of the invention may include forms of
  • an assay is a cell-based assay in which a cell which expresses a membrane-bound form of TANGO 130 protein, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a TANGO 130 protein determined.
  • test compounds can be labeled with 125 1, 35 S, 14 C, or 3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by scintillation counting.
  • test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.
  • the assay comprises contacting a cell which expresses a membrane-bound form of TANGO 130 protein, or a biologically active portion thereof, on the cell surface with a known compound which binds TANGO 130 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a TANGO 130 protein, wherein determining the ability of the test compound to interact with a TANGO 130 protein comprises determining the ability of the test compound to preferentially bind to TANGO 130 or a biologically active portion thereof as compared to the known compound.
  • an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of TANGO 130 protein, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the TANGO 130 protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of TANGO 130 or a biologically active portion thereof can be accomplished, for example, by determining the ability of the TANGO 130 protein to bind to or interact with a TANGO 130 target molecule.
  • a "target molecule" is a molecule with which a
  • TANGO 130 protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a TANGO 130 protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule.
  • a TANGO 130 target molecule can be a non-TANGO 130 molecule or a TANGO 130 protein or polypeptide of the present invention.
  • a TANGO 130 target molecule is a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a membrane-bound TANGO 130 molecule) through the cell membrane and into the cell.
  • the target for example, can be a second intercellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with TANGO 130.
  • Determining the ability of the TANGO 130 protein to bind to or interact with a TANGO 130 target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the TANGO 130 protein to bind to or interact with a TANGO 130 target molecule can be accomplished by determining the activity of the target molecule.
  • the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., intracellular Ca 2+ , diacylglycerol, IP 3 , etc.), detecting catalytic/enzymatic activity of the target on an appropriate substrate, detecting the induction of a reporter gene (e.g., a TANGO 130- responsive regulatory element operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cellular differentiation, or cell proliferation.
  • a reporter gene e.g., a TANGO 130- responsive regulatory element operably linked to a nucleic acid encoding a detectable marker, e.g., luciferase
  • detecting a cellular response for example, cellular differentiation, or cell proliferation.
  • an assay of the present invention is a cell- free assay comprising contacting a TANGO 130 protein or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the TANGO 130 protein or biologically active portion thereof. Binding of the test compound to the TANGO 130 protein can be determined either directly or indirectly as described above.
  • the assay includes contacting the TANGO 130 protein or biologically active portion thereof with a known compound which binds TANGO 130 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a TANGO 130 protein, wherein determining the ability of the test compound to interact with a TANGO 130 protein comprises determining the ability of the test compound to preferentially bind to TANGO 130 or biologically active portion thereof as compared to the known compound.
  • an assay is a cell-free assay comprising contacting TANGO 130 protein or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the TANGO 130 protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of TANGO 130 can be accomplished, for example, by determining the ability of the TANGO 130 protein to bind to a TANGO 130 target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of TANGO 130 can be accomplished by determining the ability of the TANGO 130 protein to further modulate a TANGO 130 target molecule.
  • the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as previously described.
  • the cell-free assay comprises contacting the TANGO 130 protein or biologically active portion thereof with a known compound which binds TANGO 130 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a TANGO 130 protein, wherein determining the ability of the test compound to interact with a TANGO 130 protein comprises determining the ability of the TANGO 130 protein to preferentially bind to or modulate the activity of a TANGO 130 target molecule.
  • the cell- free assays of the present invention are amenable to use of both soluble or membrane-bound forms of TANGO 130.
  • cell-free assays comprising a membrane-bound form of TANGO 130
  • non-ionic detergents such as n-octyl
  • TANGO 130 it may be desirable to immobilize either TANGO 130 or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.
  • Binding of a test compound to TANGO 130, or interaction of TANGO 130 with a target molecule in the presence and absence of a candidate compound can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes.
  • a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix.
  • glutathione-S-transferase/ TANGO 130 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or TANGO 130 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of TANGO 130 binding or activity determined using standard techniques.
  • TANGO 130 or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin.
  • Biotinylated TANGO 130 or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • antibodies reactive with TANGO 130 or target molecules but which do not interfere with binding of the TANGO 130 protein to its target molecule can be derivatized to the wells of the plate, and unbound target or TANGO 130 trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies reactive with the TANGO 130 or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the TANGO 130 or target molecule.
  • modulators of TANGO 130 expression are identified in a method in which a cell is contacted with a candidate compound and the expression of TANGO 130 mRNA or protein in the cell is determined.
  • the level of expression of TANGO 130 mRNA or protein in the presence of the candidate compound is compared to the level of expression of TANGO 130 mRNA or protein in the absence of the candidate compound.
  • the candidate compound can then be identified as a modulator of TANGO 130 expression based on this comparison. For example, when expression of TANGO 130 mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of TANGO 130 mRNA or protein expression.
  • the candidate compound when expression of TANGO 130 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of TANGO 130 mRNA or protein expression.
  • the level of TANGO 130 mRNA or protein expression in the cells can be determined by methods described herein for detecting TANGO 130 mRNA or protein.
  • the TANGO 130 proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos et al. (1993) Cell 72:223; Madura et al. (1993) J. Biol. Chem. 268:12046; Bartel et al. (1993) BioTechniques 14:920; Iwabuchi et al. (1993) Oncogene 8:1693; and PCT Publication No. WO
  • TANGO 130-binding proteins proteins which bind to or interact with TANGO 130
  • TANGO 130-bp proteins which bind to or interact with TANGO 130
  • Such TANGO 130-binding proteins are also likely to be involved in the propagation of signals by the TANGO 130 proteins as, for example, upstream or downstream elements of the TANGO 130 pathway.
  • This invention further pertains to novel agents identified by the above- described screening assays and uses thereof for treatments as described herein.
  • Detection Assays Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.
  • TANGO 130 nucleic acid molecules described herein or fragments thereof can be used to map the location of TANGO 130 genes on a chromosome.
  • the mapping of the TANGO 130 sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.
  • TANGO 130 genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the TANGO 130 sequences. Computer analysis of TANGO 130 sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the TANGO 130 sequences will yield an amplified fragment.
  • Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow (because they lack a particular enzyme), but in which human cells can grow, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio et al. (1983) Science 220:919). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.
  • PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the TANGO 130 sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a TANGO 130 sequence to its chromosome include in situ hybridization (described in Fan et al. (1990) Proc. Natl. Acad. Sci. USA 87:6223), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.
  • Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step.
  • Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical, e.g., colcemid, that disrupts the mitotic spindle.
  • the chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually.
  • the FISH technique can be used with a DNA sequence as short as 500 or 600 bases.
  • clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection.
  • 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time.
  • Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.
  • SUBSTTTUTE SHEET (RULE 26) Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland et al. (1987) Nature 325:783.
  • differences in the DNA sequences between individuals affected and unaffected with a disease associated with the TANGO 130 gene can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.
  • the TANGO 130 sequences of the present invention can also be used to identify individuals from minute biological samples.
  • the United States military for example, is considering the use of restriction fragment length polymo ⁇ hism (RFLP) for identification of its personnel.
  • RFLP restriction fragment length polymo ⁇ hism
  • an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification.
  • This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult.
  • SUBSTTTUTE SHEET (RULE 26) sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).
  • sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome.
  • the TANGO 130 sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.
  • Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences.
  • the sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue.
  • the TANGO 130 sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases.
  • Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification pu ⁇ oses.
  • SEQ ID NO:7 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:8 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.
  • a panel of reagents from TANGO 130 sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual.
  • positive identification of the individual, living or dead can be made from extremely small tissue samples.
  • DNA-based identification techniques can also be used in forensic biology.
  • Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a pe ⁇ etrator of a crime.
  • PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.
  • sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual).
  • an "identification marker” i.e. another DNA sequence that is unique to a particular individual.
  • actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments.
  • Sequences targeted to noncoding regions of SEQ ID NO: 7 are particularly appropriate for this use as greater numbers of polymo ⁇ hisms occur in the noncoding regions, making it easier to differentiate individuals using this technique.
  • polynucleotide reagents include the TANGO 130 sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:7 having a length of at least 20 or 30 bases.
  • TANGO 130 sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific
  • SUBSTTTUTE SHEET tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such TANGO 130 probes can be used to identify tissue by species and/or by organ type. In a similar fashion, these reagents, e.g., TANGO 130 primers or probes can be used to screen tissue culture for contamination (i.e., screen for the presence of a mixture of different types of cells in a culture).
  • the present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trails are used for prognostic (predictive) pu ⁇ oses to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining TANGO 130 protein and/or nucleic acid expression as well as TANGO 130 activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant TANGO 130 expression or activity.
  • a biological sample e.g., blood, serum, cells, tissue
  • the invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with TANGO 130 protein, nucleic acid expression or activity. For example, mutations in a TANGO 130 gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive pu ⁇ ose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with TANGO 130 protein, nucleic acid expression or activity.
  • Another aspect of the invention provides methods for determining TANGO 130 protein, nucleic acid expression or TANGO 130 activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics").
  • SUBSTTTUTE SHEET (RULE 26) Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.) Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of TANGO 130 in clinical trials.
  • agents e.g., drugs
  • An exemplary method for detecting the presence or absence of TANGO 130 in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting TANGO 130 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes TANGO 130 protein such that the presence of TANGO 130 is detected in the biological sample.
  • a preferred agent for detecting TANGO 130 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to TANGO 130 mRNA or genomic DNA.
  • the nucleic acid probe can be, for example, a full-length TANGO 130 nucleic acid, such as the nucleic acid of SEQ ID NO: 7, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to TANGO 130 mRNA or genomic DNA.
  • a full-length TANGO 130 nucleic acid such as the nucleic acid of SEQ ID NO: 7, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to TANGO 130 mRNA or genomic DNA.
  • Other suitable probes for use in the diagnostic assays of the invention are described herein.
  • a preferred agent for detecting TANGO 130 protein is an antibody capable of binding to TANGO 130 protein, preferably an antibody with a detectable label.
  • Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab') 2 ) can be used.
  • the term "labeled", with regard to the probe or antibody, is
  • SUBSTTTUTE SHEET intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
  • indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
  • biological sample is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.
  • the detection method of the invention can be used to detect TANGO 130 mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of TANGO 130 mRNA include Northern hybridizations and in situ hybridizations.
  • in vitro techniques for detection of TANGO 130 protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.
  • In vitro techniques for detection of TANGO 130 genomic DNA include Southern hybridizations.
  • in vivo techniques for detection of TANGO 130 protein include introducing into a subject a labeled anti-TANGO 130 antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • the biological sample contains protein molecules from the test subject.
  • the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject.
  • a preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
  • the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting TANGO 130 protein, mRNA, or genomic DNA, such that the presence of TANGO 130 protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of TANGO 130 protein, mRNA or genomic DNA in the control sample with the presence of TANGO 130 protein, mRNA or genomic DNA in the test sample.
  • the invention also encompasses kits for detecting the presence of
  • kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of TANGO 130 (e.g., a cell differentiation or cell proliferation disorder).
  • the kit can comprise a labeled compound or agent capable of detecting TANGO 130 protein or mRNA in a biological sample and means for determining the amount of TANGO 130 in the sample (e.g., an anti-TANGO 130 antibody or an oligonucleotide probe which binds to DNA encoding TANGO 130, e.g., to SEQ ID NO:7).
  • Kits can also include instructions for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of TANGO 130 if the amount of TANGO 130 protein or mRNA is above or below a normal level.
  • the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to TANGO 130 protein; and, optionally, (2) a second, different antibody which binds to TANGO 130 protein or the first antibody and is conjugated to a detectable agent.
  • a first antibody e.g., attached to a solid support
  • a second, different antibody which binds to TANGO 130 protein or the first antibody and is conjugated to a detectable agent.
  • the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labelled oligonucleotide, which hybridizes to a TANGO 130 nucleic acid sequence or (2) a pair of primers useful for amplifying a TANGO 130 nucleic acid molecule.
  • an oligonucleotide e.g., a detectably labelled oligonucleotide, which hybridizes to a TANGO 130 nucleic acid sequence
  • a pair of primers useful for amplifying a TANGO 130 nucleic acid molecule.
  • the kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent.
  • the kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate).
  • the kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained.
  • Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of TANGO 130.
  • the methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant TANGO 130 expression or activity.
  • the assays described herein such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with TANGO 130 protein and/or nucleic acid expression or activity, e.g., a disorder characterized by aberrant TANGO 130 protein or nucleic acid expression marked by abnormal cellular growth or by abnormal development.
  • the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder.
  • test sample refers to a biological sample obtained from a subject of interest.
  • a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.
  • the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant TANGO 130 expression or activity.
  • an agent e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
  • agents e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
  • agents e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate
  • such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease TANGO 130 activity).
  • the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant TANGO 130 expression or activity in which a test sample is obtained and TANGO 130 protein or nucleic acid is detected (e.g., wherein the presence of TANGO 130 protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant TANGO 130 expression or activity).
  • the methods of the invention can also be used to detect genetic lesions or mutations in a TANGO 130 gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation.
  • the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion or mutation characterized by at least one of an alteration affecting the integrity of a gene encoding a TANGO 130-protein, or the mis-expression of the TANGO 130 gene.
  • such genetic lesions or mutations can be detected by ascertaining the existence of at least one of: 1) a deletion of one or more nucleotides from a TANGO 130 gene; 2) an addition of one or more nucleotides to a TANGO 130 gene; 3) a substitution of one or more nucleotides of a TANGO 130 gene; 4) a chromosomal rearrangement of a TANGO 130 gene; 5) an alteration in the level of a messenger RNA transcript of a TANGO 130 gene; 6) an aberrant modification of a TANGO 130 gene, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a TANGO 130 gene; 8) a non-wild type level of a TANGO 130-protein; 9) an allelic loss of a TANGO 130 gene; and 10) an inappropriate post-translational modification of a TANGO 130-protein.
  • detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci. USA 91 :360), the latter of which can be particularly useful for detecting point mutations in the TANGO 130 gene (see, e.g., Abravaya et al.
  • PCR polymerase chain reaction
  • LCR ligation chain reaction
  • This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a TANGO 130 gene under conditions such that hybridization and amplification of the TANGO 130-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.
  • nucleic acid e.g., genomic, mRNA or both
  • Alternative amplification methods include: self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874), transcriptional amplification system (Kwoh, et al. (1989) Proc. Natl Acad. Sci. USA 86:1173), Q-Beta Replicase (Lizardi et al. (1988) BioTechniques 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.
  • mutations in a TANGO 130 gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified
  • SUBSTTTUTE SHEET (RULE 26) (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA.
  • sequence specific ribozymes see, e.g., U.S. Patent No. 5,498,531 can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.
  • genetic mutations in TANGO 130 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) Human Mutation 7:244; Kozal et al. (1996) Nature Medicine 2:753).
  • genetic mutations in TANGO 130 can be identified in two-dimensional arrays containing light- generated DNA probes as described in Cronin et al, supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes.
  • This step allows the identification of point mutations.
  • This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected.
  • Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.
  • any of a variety of sequencing reactions known in the art can be used to directly sequence the TANGO 130 gene and detect mutations by comparing the sequence of the sample TANGO 130 with the corresponding wild-type (control) sequence.
  • Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc. Natl Acad. Sci. USA 74:5463). It is also contemplated that any of a variety of a variety of sequencing reactions known in the art can be used to directly sequence the TANGO 130 gene and detect mutations by comparing the sequence of the sample TANGO 130 with the corresponding wild-type (control) sequence.
  • Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc. Natl Acad. Sci. USA 74:5463). It is also contemplated that
  • SUBSTTTUTE SHEET (RULE 26) automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) BioTechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT Publication No. WO 94/16101 ; Cohen et al. (1996) Adv. Chromatogr. 36:127; and Griffin et al. (1993) Appl. Biochem. Biotechnol 38:147).
  • RNA/RNA or RNA/DNA heteroduplexes Other methods for detecting mutations in the TANGO 130 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242).
  • the technique of "mismatch cleavage" entails providing heteroduplexes formed by hybridizing (labeled) RNA or
  • RNA/DNA duplexes can be treated with RNase to digest mismatched regions, and DNA/DNA hybrids can be treated with SI nuclease to digest mismatched regions.
  • either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions.
  • the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton et al. (1988) Proc. Natl. Acad. Sci. USA 85:4397; Saleeba et al. (1992) Methods Enzymol 217:286.
  • the control DNA or RNA can be labeled for detection.
  • the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in TANGO 130 cDNAs obtained from samples of cells.
  • DNA mismatch repair enzymes
  • the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at
  • a probe based on a TANGO 130 sequence e.g., a wild-type TANGO 130 sequence
  • a cDNA or other DNA product from a test cell(s).
  • the duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.
  • alterations in electrophoretic mobility will be used to identify mutations in TANGO 130 genes.
  • single strand conformation polymo ⁇ hism may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc. Nat Acad. Sci. USA 86:2766; see also Cotton (1993) Mutat. Res. 285:125; Hayashi (1992) Genet. Anal Tech. Appl 9:73). Single-stranded DNA fragments of sample and control TANGO 130 nucleic acids will be denatured and allowed to renature.
  • the secondary structure of single-stranded nucleic acids varies according to sequence, and the resulting alteration in electrophoretic mobility enables the detection of even a single base change.
  • the DNA fragments may be labeled or detected with labeled probes.
  • the sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence.
  • the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet. 7:5).
  • the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495).
  • DGGE denaturing gradient gel electrophoresis
  • DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC- rich DNA by PCR.
  • a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys. Chem. 265:12753).
  • oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl. Acad. Sci. USA 86:6230).
  • Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.
  • Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent or reduce polymerase extension (Prossner (1993) Tibtech 11:238).
  • amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.
  • the methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a TANGO 130 gene.
  • any cell type or tissue preferably peripheral blood leukocytes, in which TANGO 130 is expressed may be utilized in the prognostic assays described herein.
  • Agents, or modulators which have a stimulatory or inhibitory effect on TANGO 130 activity can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g., cell proliferation or cell differentiation disorders) associated with aberrant TANGO 130 activity.
  • disorders e.g., cell proliferation or cell differentiation disorders
  • the pharmacogenomics i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug
  • Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
  • the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of TANGO 130 protein, expression of TANGO 130 nucleic acid, or mutation content of TANGO 130 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
  • Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2) :254. In general, two types of pharmacogenetic conditions can be
  • SUBSTTTUTE SHEET (RULE 26) differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body are referred to as “altered drug action.” Genetic conditions transmitted as single factors altering the way the body acts on drugs are referred to as “altered drug metabolism”. These pharmacogenetic conditions can occur either as rare defects or as polymo ⁇ hisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.
  • G6PD glucose-6-phosphate dehydrogenase deficiency
  • the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action.
  • drug metabolizing enzymes e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19
  • NAT 2 N-acetyltransferase 2
  • CYP2D6 and CYP2C19 cytochrome P450 enzymes
  • the gene coding for CYP2D6 is highly polymo ⁇ hic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, a PM will show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite mo ⁇ hine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses.
  • TANGO 130 protein activity of TANGO 130 protein, expression of TANGO 130 nucleic acid, or mutation content of TANGO 130 genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.
  • pharmacogenetic studies can be used to apply genotyping of polymo ⁇ hic alleles encoding drug- metabolizing enzymes to the identification of an individual's drug responsiveness phenotype.
  • Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of TANGO 130 can be applied not only in basic drug screening, but also in clinical trials.
  • agents e.g., drugs, compounds
  • the effectiveness of an agent, as determined by a screening assay as described herein, to increase TANGO 130 gene expression, protein levels or protein activity can be monitored in clinical trials of subjects exhibiting decreased TANGO 130 gene expression, protein levels, or protein activity.
  • the effectiveness of an agent, as determined by a screening assay, to decrease TANGO 130 gene expression, protein levels or protein activity can be monitored in clinical trials of subjects exhibiting increased TANGO 130 gene expression, protein levels, or protein activity.
  • TANGO 130 expression or activity and preferably, that of other genes that have been implicated in for example, a cellular proliferation disorder can be used as a marker of the immune responsiveness of a particular cell.
  • genes including TANGO 130, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates TANGO 130 activity (e.g., as identified in a screening assay described herein) can be identified.
  • an agent e.g., compound, drug or small molecule
  • TANGO 130 activity e.g., as identified in a screening assay described herein
  • cells can be isolated and RNA prepared and analyzed for the levels of expression of TANGO 130 and other genes implicated in the disorder.
  • the levels of gene expression can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of TANGO 130 or other genes.
  • the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.
  • the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a TANGO 130 protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the TANGO 130 protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the TANGO 130 protein, mRNA, or genomic DNA in the pre-administration sample with the TANGO 130 protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject
  • an agent
  • increased administration of the agent may be desirable to increase the expression or activity of TANGO 130 to higher levels than detected, i.e., to increase the effectiveness of the agent.
  • decreased administration of the agent may be desirable to decrease expression or activity of TANGO 130 to lower levels than detected, i.e., to decrease the effectiveness of the agent.
  • the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant TANGO 130 expression or activity.
  • disorders include developmental disorders and growth disorders, e.g., cancer.
  • the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant TANGO 130 expression or activity, by administering to the subject an agent which modulates TANGO 130 expression or at least one TANGO 130 activity.
  • Subjects at risk for a disease which is caused or contributed to by aberrant TANGO 130 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
  • Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the TANGO 130 aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
  • a TANGO 130 agonist or TANGO 130 antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.
  • the modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of TANGO 130 protein activity associated with the cell.
  • An agent that modulates TANGO 130 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a TANGO 130 protein, a peptide, a TANGO 130 peptidomimetic, or other small molecule.
  • the agent stimulates one or more of the biological activities of TANGO 130 protein.
  • stimulatory agents include active TANGO 130 protein and a nucleic acid molecule encoding TANGO 130 that has been introduced into the cell.
  • the agent inhibits one or more of the biological activities of TANGO 130 protein.
  • inhibitory agents include antisense TANGO 130 nucleic acid molecules and anti-TANGO 130 antibodies.
  • the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) TANGO 130 expression or activity.
  • an agent e.g., an agent identified by a screening assay described herein
  • the method involves administering a TANGO 130 protein or nucleic acid molecule as therapy to compensate for reduced or aberrant TANGO 130 expression or activity.
  • Stimulation of TANGO 130 activity is desirable in situations in which TANGO 130 is abnormally downregulated and/or in which increased TANGO 130 activity is likely to have a beneficial effect. Conversely, inhibition of TANGO 130 activity is desirable in situations in which TANGO 130 is abnormally upregulated and/or in which decreased TANGO 130 activity is likely to have a beneficial effect.
  • Murine TANGO 130 was identified in a murine hypothalamus cDNA library. This murine TANGO 130 gene was used to identify a human TANGO 130 gene. The identification and sequencing of both genes is described in this example.
  • DNase solution 20 mM MgCl 2 , 2 mM DTT, 0.1 units DNase, 0.6 units RNase inhibitor in TE
  • RNA was then extracted with phenol-chloroform-isoamyl alcohol, and ethanol precipitated. After quantitation at 260 nm, an aliquot was electrophoresed to check the integrity of the RNA.
  • PolyA + RNA was isolated using an Oligotex-dT kit from Qiagen (Chatsworth, CA) as described by the manufacturer. After quantitation, the mRNA was precipitated in ethanol and resuspended at a concentration of 1 mg/ml in water.
  • cDNA Library Construction The isolated hypothalamus mRNA described above was used to prepare cDNA as follows. Hypothalamus mRNA was used as a template for preparation of cDNA according to the method of Gubler et al. (1983) Gene 25:263 using a Superscript Plasmid cDNA synthesis kit (Gibco BRL; Gaithersburg, MD). The cDNA obtained was ligated into the Notl/Sall sites of the mammalian expression vector pMET7, a modified version of pME18S, which utilizes the SRa promoter as described previously (Takebe (1988) Mol. Cell. Bio. 8:466). Ligated cDNA was transformed into electrocompetent DH10B E. coli either prepared by standard procedures or obtained from Gibco BRL.
  • DNA Preparation and Sequence Analysis A number of cDNA clones in the murine hypothalamus library were sequenced to identify sequences of interest. The identified sequences were then used to clone and sequence a complete murine TANGO 130 gene. The identification and analysis were performed as follows. First, 96-well plates were inoculated with individual hypothalamus library transformants in 1 ml of LB-amp. These inoculations were based on the titers of the cDNA transformants. The resulting cultures were grown for 15 to 16 hours at 37°C with aeration. Prior to DNA preparation, 100 ml of cell suspension was removed and added to 100 ml of 50% glycerol, mixed and stored at -80°C (glycerol freeze plate). DNA was then prepared using the
  • the insert cDNAs of a number of clones were sequenced by standard, automated fluorescent dideoxynucleotide sequencing using dye- primer chemistry (Applied Biosystems, Inc., Foster City, CA) on Applied Biosystems 373 and 377 sequenators (Applied Biosystems, Foster City, CA).
  • the primer used in this sequencing was proximal to the SRa promoter of the vector and therefore selective for the 5' end of the clones, although other primers with this selectivity can also be used.
  • the short cDNA sequences obtained in this manner were screened as follows.
  • each sequence was checked to determine if it was a bacterial, ribosomal, or mitochondrial contaminant. Such sequences were excluded from the subsequent analysis.
  • sequence artifacts such as vector and repetitive elements, were masked and/or removed from each sequence.
  • the remaining sequences were searched against a copy of the GenBankTM nucleotide database using the BLASTN program (BLASTN 1.3MP: Altschul et al. (1990) J. Mol. Bio. 215:403).
  • the sequences were analyzed against a non-redundant protein database with the BLASTX program (BLASTX 1.3MP: Altschul et al., supra).
  • This protein database is a combination of the Swiss-Prot, PIR, and NCBI GenPept protein databases.
  • the BLASTX program was run using the default BLOSUM-62 substitution matrix with the filter parameter: "xnu+seg". The score cutoff utilized was 75.
  • TANGO 130 The protein encoded by this clone was named TANGO 130.
  • the first approximately 24 amino acids in this open reading frame were predicted to be a signal sequence using the method of Von Heijne (1990) J. Membrane Biol. 115:195.
  • the amino-terminal portion of murine TANGO 130 has significant homology to MIA/CD-RAP. This portion is 37% identical to mouse MIA based on a primary sequence alignment of residues 1 to 125 of murine TANGO 130 with murine MIA. The same portion of murine TANGO 130 shows 36% identity to human MIA.
  • a human heart cDNA library was probed using standard techniques (Sambrook et al. supra) using a 32 P-labeled DNA fragment encoding the full-length mouse TANGO 130. This resulted in the identification of a human ( Figures 3A-3B) containing an approximately 1.2 kb insert and showing a high degree of homology to the mouse TANGO 130.
  • This clone named human TANGO 130, encodes a polypeptide containing an N-terminal MIA homology domain, with approximately 37% identity to mouse MIA and 38% identity to human MIA.
  • Human TANGO 130 however,
  • SUBSTTTUTE SHEET (RULE 26) does not appear to encode the full length human TANGO 130, but lacks coding sequence for approximately 300 amino acids at the carboxy terminus.
  • Northern analysis was used to examine TANGO 130 expression in mouse tissues as follows.
  • Northern blots Mae Multiple Tissue Northern Blot, Cat.# 7762-1 and Mouse Embryo Multiple Tissue Northern Blot, Cat.# 7763-1 ; Clontech, Palo Alto, CA
  • 2 ⁇ g of poly A+ RNA per lane were probed using standard techniques (Chirgwin et al. (1979) Biochemistry 18:5294) with a 32 P-labeled DNA fragment encoding the full-length TANGO 130.
  • This Northern analysis revealed that an approximately 7 kb TANGO 130 mRNA is expressed in liver, heart, testis, skeletal muscle and brain. This same Northern analysis also revealed the presence of a 1 kb message in testis. These messages are likely to represent alternatively spliced forms of TANGO 130 or the transcription products of related genes. Additionally, an approximately 7 kb message was detected in day 7, day 11, day 15 and day 17 mouse embryo, with highest expression appearing at day 7. Little or no expression was seen in adult spleen, lung, or kidney.
  • Northern analysis was used to examine TANGO 130 expression in human tissues as follows.
  • Northern blots Human Multiple Tissue Northern Blots, catalog numbers 7760-1 and 7766-1, Clontech, Palo Alto, CA
  • RNA per lane were probed using standard techniques (Chirgwin et al. (1979) Biochemistry 18:5294) with a 32 P-labeled DNA fragment encoding the 5' end of human TANGO 130.
  • This Northern analysis revealed that an approximately 7 kb TANGO 130 mRNA is expressed in heart, brain, placenta, lung, liver, skeletal muscle, pancreas, kidney, spleen, thymus, prostate, testis (highest expression), and uterus.
  • Northern analysis was used to examine TANGO 130 expression in human cancer tissues as follows.
  • Northern blots Human Multiple Tissue Northern Blots, catalog number 7757-1, Clontech, Palo Alto, CA
  • 2 ⁇ g of poly A+ RNA per lane were probed using standard techniques (Chirgwin et al. (1979) Biochemistry 18:5294) with a 32 P-labeled DNA fragment encoding the 5' end of human TANGO 130.
  • HL-60 promyelocytic leukemia cells
  • HeLa cervical adenocarcinoma cells
  • K562 chronic myelogenous leukemia cells
  • MOLT-4 lymphoblastic leukemia cells
  • SW480 colorectal adenocarcinoma cells
  • G361 melanoma cells
  • the predicted amino acid sequences of mouse and human TANGO 130 proteins were compared to amino acid sequences of known proteins and various motifs were identified.
  • the molecular weights of the human TANGO 130 proteins were predicted.
  • Mouse TANGO 130 ( Figures 1 A-1D; SEQ ID NO:l) isolated as described above encodes a 714 amino acid protein ( Figures 1 A- ID; SEQ ID NO:3).
  • the signal peptide prediction program SIGNALP Optimized Tool (Nielsen et al. (1997) Protein Engineering 10:1) predicted that mouse TANGO 130 includes a 24 amino acid signal peptide (amino acid 1 to about amino acid 24 of SEQ ID NO:3; SEQ ID NO:5) preceding the 690 amino acid mature protein (about amino acid 25 to amino acid 714 of SEQ ID NO:9; SEQ ID NO: 10).
  • a hydropathy plot (ProteanTM; DNASTAR Inc., Madison, WI) of mouse TANGO 130 is shown in Figure 2. This plot shows the location of the predicted signal peptide ("sp"), the location of cysteines ("cys”) and the MIA homology domain ("MIA").
  • Human TANGO 130 cDNA ( Figures 3A-3B; SEQ ID NO:7) isolated as described above encodes a 410 amino acid protein ( Figures 3A-3B; SEQ ID NO: 9). Alignment with the mouse TANGO 130 nucleotide and amino acid sequences suggests that the human TANGO 130 molecule is a partial clone.
  • the signal peptide prediction program SIGNALP Optimized Tool (Nielsen et al.
  • the program MegAlign was used to align human and mouse TANGO 130 with the MIA/CD-RAP molecules from several species.
  • mouse and human TANGO 130 have a region (amino acids 1 -125 of SEQ ID NO:3 and SEQ ID NO:9; SEQ ID NO:6 and SEQ ID NO: 12, respectively) of strong homology to MIA/CD- RAP. This region has been named the MIA homology domain.
  • the MIA homology domain contains the following consensus sequence: M(X) 6 L(X) 4-5 L(X) 19 .
  • Mature mouse TANGO 130 has a predicted MW of 75.9 kDa (78.5 kDa for immature mouse TANGO 130), not including post-translational
  • Mature partial human TANGO 130 has a predicted MW of 44.0 kDa (46.5 kDa for immature partial human TANGO 130).
  • TANGO 130 can be produced in a variety of expression systems.
  • the mature TANGO 130 peptide can be expressed as a recombinant glutathione-S-transferase (GST) fusion protein in E. coli and the fusion protein can be isolated and characterized.
  • GST glutathione-S-transferase
  • TANGO 130 can be fused to GST and this fusion protein can be expressed in E. coli strain PEB199.
  • Expression of the GST-TANGO 130 fusion protein in PEB199 can be induced with IPTG.
  • the recombinant fusion protein can be purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads.
  • Cells that can be used to examine effects of TANGO 130 on tumor cell proliferation and tumorigenicity include the human melanoma cell lines WM-266-4 (ATCC Accession Number CRL 1676), G-361 (ATCC Accession Number CRL 1424), and SK-MEL-3 (ATCC Accession Number HTB 69). Other cells include the human astrocytoma glioblastoma line U-373 MG (ATCC Accession Number HTB 17).
  • cells e.g., NTH-3T3 cells (ATCC Accession Number CRL 6442) may be transformed by, e.g., transfection with, e.g., the polyoma virus middle T antigen; by treatment with transforming agents, e.g., phorbol esters; or by mutation of genes involved in tumor suppression, e.g. mutation of p53.
  • transfection e.g., the polyoma virus middle T antigen
  • transforming agents e.g., phorbol esters
  • mutation of genes involved in tumor suppression e.g. mutation of p53.
  • Tumor cell proliferation following mitogenic stimulation can be measured as follows. 3 H- thymidine inco ⁇ oration is measured after 100 ⁇ l tumor cell cultures are pulsed for 6 hours with 0.5 ⁇ Ci 3 H-thymidine (Amersham Co ⁇ ., Arlington
  • Viable cell numbers are determined by trypan blue exclusion or by staining cultures with propidium iodide (PI), adding a known number of FACS calibration beads (Flow Cytometry Standards Co ⁇ ., Research Triangle Park, NC) and analyzing the samples on a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA). Beads and viable (PI negative) cells are distinguished by their different forward and side light scattering properties and the ratio of the two is used to calculate the concentration of live cells in the cultures.
  • PI propidium iodide
  • Cells undergoing DNA synthesis are identified by addition of 3 H- thymidine or BrdU (Boehringer Mannheim Biochemicals, Indianapolis, IN) to culture medium. Tumor cells are transfected with 10 ⁇ g of plasmid DNAs. After 24 hours, cells are harvested with Trypsin-EDTA solution (Irvine Scientific, Santa Ana, CA), seeded into 24-well plates, and either 10 ⁇ Ci/ml 3 H-thymidine or 10 ⁇ M BrdU is added. Cultures are continued for 24 hours to increase the yield of labeled cells compared with that obtained with shorter pulse-labelings.
  • 3 H- thymidine or BrdU Boehringer Mannheim Biochemicals, Indianapolis, IN
  • the 3 H-thymidine-labeled cells are harvested by rinsing cell monolayers with ice-cold phosphate-buffered saline (PBS) and applying 1 ml of 10%) TCA. Precipitated DNA is recovered by centrifugation at 16,000 X g for 10 minutes, washed with 5% TCA three times and solubilized in 0.5 ml of 0.5 M NaOH. After neutralization by addition of 0.25 ml of 0.1 N HCl, DNA inco ⁇ orated radioactivity is determined by scintillation counting. BrdU- labeled cells are fixed in 70% ethanol containing 20 mM glycine (pH 2.0) for 20 minutes at -20°C.
  • Inco ⁇ orated BrdU is detected by an immunofluorescence method involving incubation for 30 minutes with 6 ⁇ g/ml of a mouse anti-BrdU primary antibody (Boehringer Mannheim Biochemicals), followed by 1 :50 (v/v) of FITC-labeled goat anti-mouse immunoglobulin (DAKO Co ⁇ ., Ca ⁇ interia, CA). The proportion of positive nuclei is assessed based on analysis of at least 1000 cells. Inco ⁇ oration of 3 H-thymidine or BrdU reflects the level of cell proliferation in response to treatment of cells with TANGO 130 molecules. Soft Agar Assays to Measure TANGO 130 Tumor Formation.
  • Soft agar assays can be performed as follows. Vector control and TANGO 130 transfected cells are plated in soft agar and scored for growth after 4 weeks. A 3% solution of agar (at 56°C) is diluted to a final concentration of 0.6% with growth medium (at 56°C), pipetted into tissue culture dishes and allowed to solidify at room temperature for 20-30 minutes. At this time, approximately 2 X 10 5 cells in a volume of 50 ⁇ l are mixed with 0.3%) agar (diluted with growth medium at 40°C), pipetted gently onto the bottom agar layer and allowed to solidify for 20-25 minutes at room temperature.
  • the plates are incubated at 37°C in a 5% CO? atmosphere. Fresh top agar is added once a week. After 4 weeks the plates are stained with neutral red. Stained "colonies” or “foci” of greater than, e.g., eight cells, are counted in TANGO 130 tranfected cells and compared to vector-only transfected or non-transfected cells. The appearance of colonies or foci in soft agar demonstrates growth that is anchorage independent, a hallmark of cellular transformation.
  • TANGO 130 Effects of TANGO 130 on Tumor Cell Tumorigenicity.
  • the following experiments can be done to determine the tumorigenicity of TANGO 130 transfected cells in vivo.
  • Tumor cells in 0.2 ml HBSS are injected sub cutaneously over the right scapular region. Growth of subcutaneous tumors is monitored by examination of the mice every day and weekly measurement of tumors with calipers. The mice are sacrificed 2 months after injection, and tumors are processed for hematoxylin and eosin staining.
  • an experimental lung metastasis assay can be performed as follows.
  • Approximately 1 X 10 6 control or TANGO 130 transfected tumor cells in 0.2 ml of HBSS are injected i.v. into the lateral tail vein of BALB/c nude mice.
  • the mice are killed after 60 days, and tissues (e.g., the lungs) are removed, washed in water, and fixed with Bouin's solution for 24 hours to facilitate counting of tumor nodules as described previously (Radinsky et al. (1994) Oncogene 9:1887; Huang et al. (1996) Oncogene 13:2339).
  • the number of surface tumor nodules is counted under a dissecting microscope. Sections of tissues are stained with hemotoxylin and eosin to confirm that the nodules are melanoma and to identify micrometastasis.
  • the effect of TANGO 130 on the proliferation of B16 melanoma cells was studied using a recombinant Fc-TANGO 130 fusion protein and a flag tagged TANGO 130 fusion protein.
  • the B16 cells were seeded at 12,000/well in DMEM containing 10% FCS/lxGPS in 10 % CO2 and incubated for 24 hours. They were then re-fed with the same medium containing 0.5% FCS.
  • Fc-TANGO 130 fusion protein or flag tagged TANGO 130 fusion protein was added to the cell culture and the cultures were incubated for 6 days. At the end of treatment, the cells were trypsinized and quantified using a Coulter counter.
  • Flag tagged TANGO 130 fusion protein increased B16 cell proliferation by 42% when administered at 4 ⁇ g/ml. In contrast, Fc-TANGO 130 fusion protein inhibited B 16 cell proliferation by 18% when administered at 4 ⁇ g/ml.
  • a probe encoding the MIA domain of murine TANGO 130 was used to perform in situ expression analysis of murine TANGO 130. This analysis revealed that murine TANGO 130 expression is highest in liver, testes, ovary, and the submandibular gland. The fact that expression was observed in liver and testes is consistent with the results of Northern blot analysis (Example 2). However, the in situ expression analysis did not detect TANGO 130 expression in the heart while the Northern blot analysis revealed high level TANGO 130 expression in the heart.
  • the in situ expression analysis revealed expression of TANGO 130 in the following adult murine tissues: brain (signal slightly above background, most noticeable in the olfactory bulb), eye and harderian gland (signal observed in the retina), submandibular gland (strong, ubiquitous signal), stomach (signal observed in the mucosal epithelium), liver (strong, ubiquitous signal), kidney (signal, slightly above background), adrenal gland (signal slightly above background and slightly stronger signal in the medulla), colon (signal above background in the muscle layer), small intestine (signal above background), thymus (ubiquitous signal above background), lymph node (ubiquitous signal above background), testes (strong signal that outlines the seminiferous vesicles), ovaries (strong multifocal signal), placenta (ubiquitous signal that is stronger in the decidua region).
  • No expression was detected in the following tissues: spinal cord, white fat, brown fat, heart, lung, spleen, pancreas, skeletal muscle, and bladder.
  • Example 8 Identification of Tissues having TANGO 130 Binding Sites.
  • Two different alkaline phosphatase-murine TANGO 130 fusion proteins were used to identify tissues having TANGO 130 binding sites.
  • One fusion protein consisted of alkaline phosphatase fused to the N-terminus of murine TANGO 130 (AP-mT130) and the other fusion protein consisted of alkaline phosphatase fused to the C-terminus of murine TANGO 130 (mT130- AP).
  • the screening of tissue sections with the fusion proteins was performed essentially as described previously (Cheng and Flanagan (1994) Cell 79:157- 168).
  • tissue sections (8 ⁇ m) were prepared and rinsed in HBHA (Hank's balanced salt solution supplemented with 20 mM Hepes, pH 7, 0.05% BSA and 0.1% sodium azide). The tissue sections were then incubated for 1 h at RT with supernatant containing AP-mT130, mT130-AP or alkaline phosphatase (AP) at a concentration of 5 nM.
  • HBHA Hortas balanced salt solution supplemented with 20 mM Hepes, pH 7, 0.05% BSA and 0.1% sodium azide.
  • AP alkaline phosphatase
  • tissue sections were washed six times in HBHA, fixed in a solution containing 60% acetone, 3% formaldehyde and 20 mM Hepes, pH 7.5, washed three times in HBS (20 mM Hepes, pH 7.5, 150 mM NaCl) and then heated for 30 min at 65°C to inactivate endogenous alkaline phosphatase activity.
  • Bound AP and AP fusion protein was detected by developing sections in BCIP/NBT substrate solution (100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl, 0.17 mg/ml BCIP and 0.33 mg/ml NBT).
  • Cell supernatant containing AP-mT130 or mT130-AP was used to screen tissue sections of embryos (day 14.5 of prenatal development), whole mice (postnatal day 1.5) and a collection of adult mouse tissues for T130 binding sites. Both AP-mT130 and mT130-AP, but not AP itself, bound to connective tissue, cartilage and bone.
  • Binding of AP-mT130 and mT130-AP was also observed in the following adult mouse tissues: esophagus (connective tissue), trachea (cartilage, connective tissue, and chondrocytes), aorta (connective tissue), eye (cornea/sclera), adrenal gland (capsule), spleen (capsule, connective tissue, and scattered cells throughout red pulp), skeletal muscle (connective tissue), skin (derma and connective tissue), testes (tunica albuginea), bladder (connective tissue), uterus/ovaries (connective tissue), kidney (connective tissue), and brain (meninges).
  • AP-mT130 and mT130-AP were also found to bind to the mouse fibroblast cell line 3T3L1 and the human chondrosarcoma cell line HTB-94 Binding of AP-mT130 and mT130-AP to tissues and cells was completely blocked in the presence of 100-fold excess of purified Fc-TANGO
  • AP-mT130 and mT130-AP were found to bind to connective tissue layers in human ovaries, testes, breast and adipose tissue. This result demonstrates that murine TANGO 130 is able to bind to human tissues.
  • Example 9 TANGO 130 is Secreted.
  • a secretion assay revealed that alkaline phosphatase TANGO 130 MIA domain fusion protein and flag tagged TANGO 130 MIA domain fusion protein are secreted from 293T cells. Briefly, 8x10 ⁇ 293T cells were plated per well in a 6-well plate and the cells were incubated in growth medium (DMEM, 10% fetal bovine serum, penicillin/strepomycin) at 37°C, 5% CO2 overnight. The 293T cells were transfected with a vector expressing a TANGO 130 fusion protein and 10 ⁇ g LipofectAMINE (GIBCO/BRL Cat. # 18324-012)/well according to the protocol for GIBCO/BRL LipofectAMINE.
  • DMEM 10% fetal bovine serum, penicillin/strepomycin
  • the transfectant was removed 5 hours later and fresh growth medium was added to allow the cells to recover overnight. The medium was removed and each well was gently washed twice with DMEM without methionine and cysteine (ICN Cat. # 16-424-54). Next, 1 ml DMEM without methionine and cysteine with 50 ⁇ Ci Trans- 35 S (ICN Cat. # 51006) was added to each well and the cells were incubated at 37°C, 5% CO2 for the appropriate time period.
  • a 150 ⁇ l aliquot of conditioned medium was obtained and 150 ⁇ l of 2X SDS sample buffer was added to the aliquot.
  • the sample was heat-inactivated and loaded on a 4-20% SDS-PAGE gel. The gel was fixed and the presence of secreted protein was detected by autoradiography.
  • DLSHGRRFSDLK amino acids 25 to 36 of murine TANGO 130; SEQ ID NO: 13
  • EDFTGPDCRFVNFKK amino acids 54 to 68 of murine TANGO 130; SEQ ID NO: 14
  • QLDPSTGRRFSEHK (amino acids 23 to 36 of human TANGO 130; SEQ ID NO: 15); EDFTGPDCRFVNFKK (amino acids 54 to 68 of human TANGO 130; SEQ ID NO:16); and GFLELYNSAATDSE (amino acids 142 to 155 of human TANGO 130; SEQ ID NO: 17).
  • Each polyclonal antibody was affinity purified using the corresponding. These polyclonal antibodies are able to bind various TANGO 130 fusion proteins.
  • TANGO 130 The effect of TANGO 130 on embryonic development was investigated by injecting Xenopus embryos with murine TANGO 130 MIA domain (T130(MIA)) mRNA or flag tagged murine TANGO 130 MIA domain fusion protein (T130(MIA)-flag) mRNA. Briefly, capped mRNAs were synthesized using SP6 RNA polymerase and the using mMESSAGE mMACHINE kit (Ambion, Austin, TX) according to the manufacturer's instructions. Linearized plasmids encoding T130(MIA) or T130(MIA)-flag were used as templates for mRNA synthesis. In vitro transcribed capped RNA was purified using RNAesy kit (Qiagen) and analyzed by gel electrophoresis.
  • RNAesy kit Qiagen
  • Xenopus embryos were obtained by in vitro fertilization, dejellied in 2% cysteine HCl (pH 7.6), washed thoroughly in Modified Ringers solution, and incubated at 15-25°C. Embryos were transferred to injection solution (Modified Ringers solution containing 3% Ficoll) prior to injections. Next, lng and 2.5ng of T130(MIA) mRNA and T130(MIA)-flag mRNA was injected into one blastomere at the 2-cell stage. Embryos were transferred to O.lx MMR from the injection solution after approximately 6 hours and grown until the appropriate stage.
  • T130(MIA) mRNA was injected into the animal pole of each of the 2 blastomeres at the 2-cell stage.
  • Animal caps from uninjected or injected embryos were explanted at stage 9 and cultured in lx Modified Ringers containing 0.01% BSA and 50ug/ml gentamycin. Animal caps were cultured until control embryos have reached stage 23-24.
  • Animal cap tissue was lysed and total RNA was extracted using RNeasy kit (Qiagen).
  • RT-PCR was performed on these samples using gene-specific primers and appropriate annealing temperatures and the products were analyzed by gel electrophoresis. The RT-PCR analysis indicated weak induction of Sox- 17, an endodermal specific marker.
  • Example 12 Chromosomal Mapping of Murine TANGO 130.
  • Murine TANGO 130 was mapped to chromosome 5 between markers D5Mitl95 and D5Mitl5.
  • the following genes are located in this region: gprk21 (a G protein coupled receptor, kinase), addl (adducin), lx (luxate), drd5 (dopamine receptor 5), bp3 (alloantigen), qdpr (quininoid dihyropteridine reductase), sod3 (superoxide dismutase3), cckr (cholecystokinin A receptor), pgm3 (phosphoglucomutase), a ⁇ (lymphoid, erythroid hype ⁇ lasia), gckr (glucokinase regulatory protein), hdh (Huntington's homolog), and khk (ketohexokinase).
  • the region to which murine TANGO 130 maps corresponds to human 7q, 7p, 18pl, 4pl, 14q. Equivalents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouvelles molécules d'acide nucléique TANGO 130 codant pour des protéines présentant une homologie avec la protéine inhibitrice des mélanomes. L'invention concerne également des protéines de fusion TANGO 130 isolées, des peptides antigéniques et des anticorps anti-TANGO 130. L'invention concerne en outre des vecteurs contenant des molécules d'acide nucléique selon l'invention, des cellules hôtes dans lesquelles ont été introduits lesdits vecteurs et des animaux transgéniques non humains dans lesquels un gène TANGO 130 a été introduit ou disloqué. L'invention concerne enfin des méthodes de diagnostic, des méthodes d'imagerie et des méthodes thérapeutiques utilisant les compositions selon l'invention.
PCT/US1999/020032 1998-09-01 1999-09-01 Nouvelle proteine liee a la proteine inhibitrice des melanomes et utilisation de cette nouvelle proteine WO2000012762A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57020/99A AU5702099A (en) 1998-09-01 1999-09-01 A novel protein related to melanoma-inhibiting protein and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14505698A 1998-09-01 1998-09-01
US09/145,056 1998-09-01

Publications (1)

Publication Number Publication Date
WO2000012762A1 true WO2000012762A1 (fr) 2000-03-09

Family

ID=22511404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020032 WO2000012762A1 (fr) 1998-09-01 1999-09-01 Nouvelle proteine liee a la proteine inhibitrice des melanomes et utilisation de cette nouvelle proteine

Country Status (2)

Country Link
AU (1) AU5702099A (fr)
WO (1) WO2000012762A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077163A1 (fr) * 2000-03-28 2001-10-18 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 16, et polynucleotide codant pour ce polypeptide
WO2001079436A2 (fr) * 2000-03-29 2001-10-25 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 10, et polynucleotide codant pour ce polypeptide
WO2008040557A1 (fr) * 2006-10-06 2008-04-10 Scil Technology Gmbh Implant de noyau gélatineux spinal
US7402653B2 (en) 2001-07-13 2008-07-22 Cms Peptides Patent Holding Company Limited Biologically active peptides
WO2011134979A2 (fr) 2010-04-27 2011-11-03 Scil Technology Gmbh Préparation stable de mia/cd-rap
US8124054B2 (en) 2008-03-26 2012-02-28 Korea Atomic Energy Research Institute Chelating agent conjugated α-MSH peptide derivatives, preparation method thereof and composition for diagnosis and treatment of melanoma comprising the same as an active ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 20 August 1998 (1998-08-20), MARRA ET AL.: "Washu-HHMI Mouse est Project" *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077163A1 (fr) * 2000-03-28 2001-10-18 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 16, et polynucleotide codant pour ce polypeptide
WO2001079436A2 (fr) * 2000-03-29 2001-10-25 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 10, et polynucleotide codant pour ce polypeptide
WO2001079436A3 (fr) * 2000-03-29 2002-04-18 Biowindow Gene Dev Inc Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 10, et polynucleotide codant pour ce polypeptide
US7402653B2 (en) 2001-07-13 2008-07-22 Cms Peptides Patent Holding Company Limited Biologically active peptides
US7491689B2 (en) 2001-07-13 2009-02-17 Cms Peptides Patent Holding Company Limited Compositions comprising the biologically active peptide YSL
US7696152B2 (en) 2001-07-13 2010-04-13 CMS Peptides Patent Holdings Company Limited Biologically active peptide consisting of tyrosyl-seryl-leucine (YSL)
US7718768B2 (en) 2001-07-13 2010-05-18 Cms Peptides Patent Holding Company Limited Biologically active peptide PTTKTYFPHF
WO2008040557A1 (fr) * 2006-10-06 2008-04-10 Scil Technology Gmbh Implant de noyau gélatineux spinal
JP2010505482A (ja) * 2006-10-06 2010-02-25 エスシーアイエル テクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 脊髄核インプラント
US8124054B2 (en) 2008-03-26 2012-02-28 Korea Atomic Energy Research Institute Chelating agent conjugated α-MSH peptide derivatives, preparation method thereof and composition for diagnosis and treatment of melanoma comprising the same as an active ingredient
WO2011134979A2 (fr) 2010-04-27 2011-11-03 Scil Technology Gmbh Préparation stable de mia/cd-rap

Also Published As

Publication number Publication date
AU5702099A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
US20070031439A1 (en) Novel protein related to melanoma-inhibiting protein and uses thereof
US20140296101A1 (en) Secreted proteins and uses thereof
EP1009752A1 (fr) Nouvelles molecules de la famille des proteines de type tango-77 et utilisations de ces molecules
WO1999032632A1 (fr) Nouvelles molecules d'un facteur apparente a l'interleukine issu d'un embryon (edirf) et leurs utilisations
JP2003508030A (ja) 新規ポリペプチドおよびそれをコードする核酸
US6197551B1 (en) Spoil-1 protein and nucleic acid molecules and uses therefor
US6225085B1 (en) LRSG protein and nucleic acid molecules and uses therefor
EP1107987A2 (fr) Nouvelles molecules d'acides nucleiques et de polypeptides irap-bp et leurs utilisations
US6406884B1 (en) Secreted proteins and uses thereof
US20050032172A1 (en) Novel molecules of the FTHMA-070-related protein family and the T85-related protein family and uses thereof
WO2000012762A1 (fr) Nouvelle proteine liee a la proteine inhibitrice des melanomes et utilisation de cette nouvelle proteine
WO2000008045A2 (fr) Nouvelles molecules de la famille de proteines apparentees a tango-93 et leurs utilisations
WO1999054437A2 (fr) Nouvelles molecules de la famille des proteines liees a t125 et utilisations de celles-ci
US6326481B1 (en) Molecules of the AIP-related protein family and uses thereof
WO2000050443A9 (fr) Proteines secretees et leurs utilisations
EP1070081A1 (fr) Nouvelles proteines de la famille des proteines t129 et leurs utilisations
US20040248245A1 (en) Zinc activated ion channel
US20040142420A1 (en) Novel molecules of the TANGO-93-related protein family and uses thereof
EP1586660A1 (fr) Nouvelles molécules de la famille des protéines liées à T85 et utilisation des dites molécules
EP1080101A1 (fr) Nouvelles molecules de la famille de proteines associees au t139 et utilisations correspondantes
WO1999067415A1 (fr) Nouvelles molecules de la famille de proteines associees a t110 et leurs utilisations
AU2013200856A1 (en) CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses thereof
AU2006235978A1 (en) CRSP protein (Cysteine-Rich Secreted Proteins), nucleic acid molecules encoding them and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase